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ABSTRACT
HIV infection is likely to become a major cause of cardiac failure
in the early part of the next century.
This study was performed in order to evaluate the prevalence,
aetiology and natural history of heart muscle disease in a cohort of
296 HIV patients drawn from all risk groups who had serial
echocardiograms over a four year period.
Heart muscle disease was found in 14.2% of HIV patients and took
three principal forms - dilated cardiomyopathy, borderline left
ventricular dysfunction and isolated right ventricular dilation.
Dilated cardiomyopathy was associated significantly with a very
low CD4 count indicative of late stage HIV disease. It was
invariably irreversible. In contrast, some patients with borderline
left ventricular dysfunction and isolated right ventricular dilation
subsequently reverted to normal. The latter was usually related to
pressure or volume overload of the right ventricle rather than to a
primary myopathic process.
A subgroup of 173 HIV patients was assessed serologically. There
was no excess exposure to the cardiotropic organisms Toxoplasma
gondii and cytomegalovirus in any heart muscle disease group.
Indeed, there were some patients in each group who had never been
infected with either agent. It was found also that there were similar
proportions of zidovudine-treated patients in each of the heart
muscle disease groups, all of which contained individuals who had
never been exposed to this drug.
The polymerase chain reaction was used on autopsy cardiac tissue
taken from a group of 12 HIV patients with and without heart
muscle disease. HIV was present in the myocardium of 11 of these
patients and its concentration was non-significantly greater in those
with heart muscle disease. These samples of myocardium also
underwent immunohistochemistry using antibodies directed against
the HIV p24 and group 120 antigens, markers of intracellular viral
replication. There was complete absence of positive signals
suggesting that the virus which had been demonstrated within the
myocardium using the polymerase chain reaction was not
replicating.
Serum selenium was assayed in a subgroup of 60 HIV patients.
This comprised 30 patients with heart muscle disease and 30
controls matched individually for age, sex, risk group, body mass
index and stage of disease. The majority (49/60) had serum
selenium concentrations which fell below the reference interval but
there were no significant differences between heart muscle disease
patients and controls.
Survival curves were calculated and these showed that HIV patients
with dilated cardiomyopathy met a significantly earlier death from
an AIDS related condition than those from all the other groups,
even after accounting for their low CD4 count. This remained true
when patients with dilated cardiomyopathy were matched
individually with a group of patients identical in every respect
except for the presence of cardiac disease.
Heart muscle disease in HIV infection is common and takes a
number of forms. Dilated cardiomyopathy occurs in late stage
disease, is invariably irreversible and is associated with a
particularly poor prognosis. This is in contrast to borderline left
ventricular dysfunction and isolated right ventricular dilation which
occur at an earlier stage of HIV infection, are potentially reversible
and do not carry adverse prognostic implications. Neither infection
with Toxoplasma gondii and cytomegalovirus nor treatment with
zidovudine appear to have a primary role in the development of
heart muscle disease. Although HIV is often found within the
myocardium, it does not appear to replicate within this tissue. Low
serum selenium concentrations are widespread in HIV patients but





1.1 EPIDEMIOLOGY OF HIV INFECTION
The World Health Organisation estimates that since the start of the
pandemic, 14 million adults and one million children have been
infected with the human immunodeficiency virus (HIV) (WHO
press release, WHO/30, 10 April 1994). Infection results in
progressive deterioration in immune function and leads ultimately
to the acquired immune deficiency syndrome (AIDS). By July
1993, a total of 611 589 people had been reported to the World
Health Organisation as suffering from AIDS (WHO Global
Statistics, July 1993) and it has been predicted that by the end of
the century, between 30 and 40 million people will have been
infected with HIV (WHO press release, WHO/30, 10 April 1994).
In Western Europe, the highest per capita rates of AIDS are found
in Spain, France, Switzerland and Italy (6.6-8.7 cases per 100 000
people) (WHO Global Statistics, July 1993). In the United
Kingdom by the end of September 1993, 20 590 people had been
infected with HIV and 8115 cases of AIDS had been reported
(AIDS Newsletter 1993). Patients with HIV infection are
concentrated in London and the Lothians, particularly the city of
Edinburgh where it is estimated that approximately 1 in 150 people
aged between 15 and 35 harbour the virus (Brettle 1990). By
October 1993, 2025 people in Scotland had contracted HIV
(Answer 1993a) and of the 475 AIDS cases reported by December
1993, 318 had died (Answer 1993b).
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HIV is transmitted by penetrative sexual intercourse, injection drug
use with contaminated needles and syringes, administration of
infected blood and blood products, and vertically from mother to
child (Rogers and Gellin 1990, Ludlam et al 1986).
In the western world, homosexuals constitute the largest group of
patients who are HIV positive, followed by injection drug users.
This contrasts with Africa and Asia where heterosexual
transmission constitutes the predominant mode of viral spread
(Potts et al 1991). HIV infection is now endemic in many parts of
Africa and Asia where it is causing serious social and economic
disruption as increasing numbers of breadwinners and the most
productive members of society are afflicted. The HIV cohort in the
western world contracted the virus in the early 1980's. As a result,
many have either died or have developed end-stage AIDS. These
individuals are therefore destined to die relatively quickly (Gilks
1993). However, in developing countries, people have only
become infected relatively recently. As these patients pass through
the various stages of HIV disease, their requirement for ever
increasing medical support threatens to overwhelm meagre health
budgets and national economies (Potts et al 1991).
In the west, increased awareness amongst homosexuals and
modification of risk behaviour by injection drug users have resulted
in a reduction of viral spread in these groups (Davies et al 1994,
Taylor et al 1994). Unfortunately, the effects upon heterosexual
4
risk behaviour have been much less dramatic and the group
acquiring HIV infection by this route now has the highest growth
rate in the United Kingdom, albeit from a low baseline
(Communicable Disease Report 1992). A similar phenomenon is
also occurring in the USA, particularly amongst African-Americans
and Hispanics (Lifson 1994). An explosive rise in heterosexually
acquired HIV infection has already taken place in less developed
parts of the world. In Thailand, for example, HIV seropositivity in
female prostitutes has risen from 3.5% in June 1989 to 29.5% by
December 1993 (Hanenberg et al 1994).
1.2 VIROLOGY OF HIV INFECTION
There is speculation about the origin of HIV and indeed, its
contribution to AIDS. HIV is an RNA retrovirus bearing a group
120 surface antigen which binds specifically to so-called CD4
receptors on T helper lymphocytes which are an integral part of the
immune system. Recent work suggests that at least three other
receptors are implicated in HIV infection of cells including
galactosyl ceramide in brain and bowel tissue and the Fc and
complement receptors (Levy 1993). The Fc receptor in particular
has been implicated in recent work performed in the USA
(Herskowitz et al 1993b). The interaction between HIV and cell
surface receptors is not sufficient to permit viral entry into the cell
and additional mechanisms including conformational changes are
required (Levy 1990, Levy 1993).
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Once inside the cell, the virus manufactures two DNA copies of its
RNA genome which then associate to form double stranded DNA.
Viral RNA is later degraded and the double stranded DNA is
incorporated into the genome of the host cell. At this stage, HIV
enters a latent phase which may last for several years (Levy 1990,
Levy 1993). There is evidence that the virus is relatively
concentrated in lymphoid tissue during this period and that HIV
strains evolve within the host, possibly following selection by
immune responses (Levy 1990, Levy 1993). These variants
acquire the propensity to attack different organ systems and can be
reactivated within cells by stimuli including secondary infections
(Levy 1990, Levy 1993). Reactivation can result in intracellular
replication of HIV, expression of viral antigens at the host cell
surface, cytolysis and widespread dissemination of the organism
(Yarchoan and Broder 1989, Levy 1990). This was confirmed in a
recent study (Donaldson et al 1994) where it was shown that
patients with AIDS had widespread HIV infiltration of diverse
organs including the brain, lung, colon and liver. In contrast,
patients with asymptomatic HIV infection had the virus confined to
lymphoid tissues.
Once infected, a cell may carry HIV in a latent form indefinitely.
During latency, the virus is fully integrated into the host cell
genome and there are no external clues such as surface viral
antigens which can alert the immune system to its presence. This
permits the virus to be smuggled by immunocytes such as tissue
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macrophages into organs including the central nervous system
which are normally well protected from attack by invading
organisms (Levy 1990, Levy 1993).
HIV has similarities with the simian immunodeficiency virus (SIV),
a retrovirus which infects chimpanzees. It has been proposed that
HIV is a variant of SIV which has crossed the species boundary and
in so doing has been transformed from a relatively innocuous
primate virus into one which is lethal to man (Karpas 1990).
Sexual practices of certain African tribes, which include the
inoculation of monkey blood around the genital area, may have
facilitated this transfer between species (Karpas 1990).
1.3 HIV AND AIDS
There is an ongoing debate about the precise relationship between
HIV infection and the development of AIDS. Several key issues
have yet to be resolved satisfactorily. Although the predominant
immunological abnormality in late stage HIV disease is the
selective destruction of CD4 lymphocytes, only a small proportion
of these cells are actually infected (Simmonds et al 1990a). HIV is
not cytopathic in vitro and appears to be harmless in chimpanzees
(Dalgleish and Colizzi 1992). The mechanisms of cell destruction
are unknown although there is evidence of viral enhancement of
programmed cell death (apoptosis) through the stimulation of
infected macrophages to either produce tumour necrosis factor
(TNF-o:) or to cease production of interleukin-1 (Levy 1990,
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Dalgleish and Colizzi 1992, Dalgleish et al 1992, Levy 1993).
There is a long latency between infection and the onset of serious
illness. Moreover, some patients appear to remain well for a
prolonged period. It is also recognised that cases of opportunistic
infection with AIDS defining organisms and full blown immune
deficiency states can occur in patients negative for HIV (Bird 1992,
McNulty et al 1994).
These apparent paradoxes have led to speculation that HIV may be
an innocuous bystander in immune deficiency syndromes due
instead either to repeated sepsis, or to the chaotic lifestyle
associated with injection drug use or to malnutrition per se
(Duesberg 1989). It is possible that repeated bacterial and fungal
infections may occur in the context of penetrative anal intercourse
with numerous partners or with the use of contaminated injection
equipment. The immune system is weakened progressively,
rendering the body vulnerable to overwhelming sepsis by
opportunistic organisms. Areas with large numbers of HIV
infected people such as sub-Saharan Africa are also regions where
chronic debilitating infections (including tuberculosis) co-exist with
widespread malnutrition.
The consensus view, however, is that for the overwhelming
majority of HIV infected patients, a relatively brief primary illness
comprising fever, myalgia and lethargy together with a
constellation of symptoms and signs involving some or all of the
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major organ systems (Tindall et al 1991) is followed by a gradual
decline in the number of CD4 lymphocytes with concomitant
deterioration in the body's ability to mount an effective immune
response to other organisms. Patients defined as long term
survivors (those that live for more than eight years after HIV
infection) may owe their longevity to a combination of factors
including a low infectious viral load, a less cytopathic HIV strain
and a favourable mix of host immune responses (Levy 1993).
Progressive immunodeficiency is characterised by recurrent
infections, particularly with opportunistic organisms, malignancy
and organ failure. The term "AIDS" encompasses these clinical
manifestations of HIV disease. Until 1993, HIV infection was
classified by the Centers for Disease Control (CDC) in Atlanta
solely on the basis of clinical criteria. However, this has been
superseded by a matrix of nine mutually exclusive categories based
upon both clinical criteria and CD4 lymphocyte counts (Table 1.1
and Appendix 1) (Morbidity and Mortality Weekly Report 1992).
While HIV primarily infects the immune system, many organs can
be damaged directly or indirectly by the virus. Disparate effects on
the central nervous system (Price et al 1988, Simpson et al 1991),
gastrointestinal tract (Churchill 1991) and cardiovascular system
(Acierno 1989, Herskowitz and Baughman 1994) have been
described and it is now recognised that generalised spread of HIV













































































During the latent period, there is gradual destruction of the immune
system accompanied by the development of different strains of HIV
which have the potential to infect a variety of cell types (Simmonds
et al 1990b). As there is little viral replication and therefore
minimal cell surface expression of viral antigens at this time, HIV
can be transported around the body in an immunologically
protected form and enter the component cells of organ systems
including the heart.
1.4 END-ORGAN DAMAGE IN HIV INFECTION
Opportunistic infection has been one of the principal causes of
death for patients with HIV (Lifson et al 1992) but this is becoming
less important probably due to improved clinical surveillance,
better diagnostic techniques and the advent of new antimicrobial
agents. Peters et al (1991) confirmed in a retrospective study that a
progressively smaller proportion of HIV patients were dying of
opportunistic infection, and that this was accompanied by a rise in
the mortality attributable to malignancy.
Kaposi's sarcoma and high grade B cell lymphomata are the
tumours most commonly associated with HIV infection (Tirelli et al
1994). These malignancies are relatively rare in non-HIV infected
patients but have been found in over half the cases in some AIDS
post mortem series (Cammarosano and Lewis 1985). Factors which
are thought to be relevant in pathogenesis include reduced immune
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surveillance caused by the destruction of CD4 lymphocytes by HIV
and malignant transformation of B lymphocytes by other organisms
such as the Epstein Barr virus (Tirelli et al 1994).
Clinically significant end-organ damage including cardiac
dysfunction occurs predominantly in late stage HIV disease
(Corallo et al 1988). As fewer people succumb to opportunistic
infection, it is postulated (Acierno 1989, Herskowitz and
Baughman 1994) that the prevalence of heart muscle disease will
increase in a manner similar to that already described for
malignancy (Peters et al 1991). Up to 40 million people will be
HIV positive at the turn of the century (WHO press release,
WHO/30, 10 April 1994). Rutherford (1994) has speculated that it
will take 10 years for 50% of people acquiring HIV infection to
develop AIDS. Thus, if just 5% of HIV patients with late stage
disease develop significant left ventricular dysfunction, a more
conservative estimate than the 6.2% figure quoted by Herskowitz et
al (1993a), then AIDS could become a major cause of heart failure
around the world by the year 2010.
1.5 THE EFFECTS OF HIV UPON THE HEART
Cardiac disease is emerging as a significant cause of morbidity, and
possibly mortality, in HIV infection. Pericardial effusions,
malignant infiltration, endocarditis, disorders of rhythm,
myocarditis and heart muscle disease have all been described
(Acierno 1989, Herskowitz and Baughman 1994). Vascular
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phenomena such as inflammation, thrombosis and spasm have also
been reported (Joshi et al 1987).
The effects of HIV upon the heart appear to vary depending upon
geographical location, risk group and stage of disease although the
significance of the first two factors may be over-represented by
reporting bias. Much of the HIV world literature emanates from
the USA with smaller contributions from Europe, Africa and Asia.
Pericardial effusions, for example, have been reported
predominantly in indigenous Africans and relatively rarely in North
Americans (Cegielski et al 1990, Kagame et al 1990). Such
effusions are often tuberculous in origin (Cegielski et al 1990,
Kagame et al 1990) and are therefore more likely to be found in
Africa where there is poor nutrition and low herd immunity
because of a lack of comprehensive BCG vaccination.
Similarly, homosexuals in particular appear to suffer from
malignant infiltration (Tirelli et al 1994). Again however, most of
the pathological studies evaluating intracardiac Kaposi's sarcoma
and B cell lymphomata were conducted in America in the 1980's.
At that time, the predominant group afflicted with late stage HIV
infection were homosexuals.
The stage of disease is undoubtedly important. While subclinical
cardiac abnormalities do occur in early HIV infection, the most
florid manifestations, particularly heart muscle disease, occur when
patients are in the later stages of their illness or have developed
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AIDS (Corallo et al 1988, Herskowitz et al 1993a).
Accurate assessment of the prevalence and nature of cardiac
involvement in HIV disease is hampered by two factors. Firstly,
cardiac disease may be asymptomatic (Corallo et al 1988,
Lipshultz et al 1989, Blanchard et al 1991, Kavanaugh-McHugh et
al 1991, Herskowitz et al 1993a). Secondly, it may present with
features which are ascribed incorrectly to other organ systems
(Stewart et al 1989) or opportunistic infection (Fink et al 1984,
Corallo et al 1988, Lipshultz et al 1989). This is particularly true
of breathlessness which may be attributed mistakenly to respiratory
infection or anaemia.
Lipshultz et al (1989) studied 31 children using echocardiography
and found that the symptoms and signs of heart muscle disease
were obscured by hepatosplenomegaly, interstitial lung disease and
renal impairment. Moreover, some of the children with greatest
myocardial dysfunction failed to show obvious clinical evidence of
cardiac involvement. The authors recommended that routine,
serial, non-invasive assessment be performed because significant,
often occult, cardiac abnormalities were common.
The prevalence of cardiac disease will be underestimated in places
where high numbers of HIV patients and inadequate diagnostic
facilities co-exist, regrettably the case in most Third World
countries.
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Post mortem examinations are not always performed and even when
an autopsy reveals evidence of heart disease, there is a tendency to
ascribe the cause of death to opportunistic infection or malignancy.
In the post mortem series reported by Cammorasano and Lewis
(1985), Stewart et al (1989), and Lewis (1989), a total of 77
patients out of 164 (47%) had autopsy evidence of significant heart
disease, yet this was considered an important factor in the deaths of
only four of these individuals.
If heart failure is not recognised, potentially deleterious therapies
may be administered; these include blood transfusions, large
intravenous fluid loads used as a vehicle for delivering drugs and
chemotherapeutic agents for Kaposi's sarcoma derived from
anthracyclines which are recognised cardiotoxins (Himelman et al
1989a).
1.6 PERICARDITIS AND PERICARDIAL EFFUSIONS IN
HIV INFECTION
The prevalence of pericardial effusion in association with HIV
infection varies between 11% (Romeu et al 1990) and 82%
(Kagame et al 1990) and in at least one series, it was the
commonest cardiac manifestation of HIV disease (Lewis 1989).
While the majority of pericardial effusions in HIV disease are
clinically insignificant, large effusions accompanied by features of
tamponade including collapse of the right atrium and ventricle
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during late diastole may occur (Andress et al 1989, Scott et al
1990, Turco et al 1990). Cardiomegaly on a chest X-ray should
prompt early echocardiographic assessment (Fink et al 1984,
Monsuez et al 1988).
Pericardial effusions may be due to opportunistic infection,
malignant infiltration, myocarditis or heart muscle disease (Fink et
al 1984, Himelman et al 1989a, Lewis 1989). Effusions that are
not related to opportunistic infection or malignancy are often due to
general fluid overload and may be accompanied by fluid in other
serous cavities (Lewis 1989). Many such effusions are small,
asymptomatic and do not require treatment (Blanchard et al 1991)
(Figure 1.1). Clinically significant pericardial effusions are usually
due to secondary infection (Woods and Goldsmith 1989, Cegielski
et al 1990, Kagame et al 1990, Romeu et al 1990, Reynolds et al
1991) or malignant infiltration (Steigman et al 1988, Stotka et al
1989).
Organisms implicated in the pathogenesis of pericardial effusions
include opportunistic agents (Brivet et al 1987), Staphylococcus
aureus (Stechel et al 1986), viruses (Freedberg et al 1987, Toma et
al 1989, Scott et al 1990) and typical and atypical mycobacteria
(D'Cruz et al 1986, Woods and Goldsmith 1989, Cegielski et al
1990, Kagame et al 1990, Romeu et al 1990, Reynolds et al 1991).
Tamponade due to mycobacterial infection occurs most commonly
in Africa (Cegielski et al 1990, Kagame et al 1990, Reynolds et al
1991) where it is often the index diagnosis of AIDS (Dalli et al
FIGURE 1.1 Pericardial effusion in parasternal long axis and
M-mode echocardiograms (short axis view).
PE - pericardial effusion, LA - left atrium, LV - left ventricle.
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1987); however, it may also occur early in the course of HIV
infection (Cegielski et al 1990).
Pericardial disease and effusions may present with classical
symptoms such as chest pain and breathlessness, and signs
including tachycardia, praecordial rub, diminished heart sounds,
gallop rhythm, pulsus paradoxus and collapse (Dalli et al 1987,
Stotka et al 1989, Woods and Goldsmith 1989, Scott et al 1990).
Non-specific electrocardiographic (ECG) changes may occur
including ST/T wave abnormalities, electrical alternans,
prolongation of QTc and abnormal QRS morphology (Freedberg et
al 1987, Andress et al 1989, Stotka et al 1989, Woods and
Goldsmith 1989). Occasionally, purulent pericarditis may progress
to severe constrictive disease which can be cured by
pericardiectomy (Stechel et al 1986). In symptomatic and life
threatening situations, pericardiocentesis and/or pericardial biopsy
is indicated. As well as helping to identify any causative organism
against which treatment can then be directed (Turco et al 1990),
these techniques may also improve survival (Price et al 1988).
1.7 MALIGNANT INFILTRATION IN HIV DISEASE
HIV infection predisposes towards the development of neoplasia
(Tirelli et al 1994). In one series of patients with HIV infection
who had not developed AIDS, 39% were found to be suffering
from malignant disease (Acierno 1989). Cardiac involvement is
usually due to Kaposi's sarcoma or B cell lymphomata and may
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cause intractable cardiac failure, pericardial effusions and
abnormalities of conduction (Acierno 1989). Alternatively, they
may remain clinically silent and be detected only at post mortem
(Silver et al 1984, Goldfarb et al 1989).
Kaposi's sarcoma is an angiosarcoma which was found at autopsy
in 51 % of patients with full blown AIDS (Cammarosano and Lewis
1985). The tumour involved the heart in 19% of these cases.
Kaposi's sarcoma has been described predominantly in
homosexuals with HIV infection (Krigel et al 1985) and cardiac
infiltration usually but not invariably (Autran et al 1983) takes
place as part of a metastatic process (Cammarosano and Lewis
1985, Steigman et al 1988, Stotka et al 1989). The tumour may
affect the pericardium, epicardium or myocardium and sometimes
involves the coronary arteries (Silver et al 1984, Cammarosano and
Lewis 1985, Steigman et al 1988, Lewis 1989, Stotka et al 1989).
Concomitant pericardial effusion is common and may cause
tamponade (Steigman et al 1988, Stotka et al 1989). Cutaneous
Kaposi's sarcoma is often radiosensitive (Stotka et al 1989), but at
present there is no evidence that such treatment improves survival
in patients with cardiac involvement.
Primary cardiac lymphoma is rare in non-HIV patients, accounting
for less than 10% of all primary malignant cardiac tumours
(McAllister et al 1978). Although it occurs more frequently in
those with HIV infection (Balasubramanyam et al 1986,
Constantino et al 1987, Goldfarb et al 1989), it is still not as
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common as cardiac infiltration by Kaposi's sarcoma (Cammarosano
and Lewis 1985, Anderson et al 1988, Acierno 1989, Turco et al
1990). Cardiac involvement in disseminated lymphoma is also
recognised (Acierno 1989). The tumour may infiltrate the
pericardium, myocardium or endocardium alone or in combination.
Intracavitary lymphoma can also occur.
Echocardiography can be used to visualise pericardial effusions and
intracavitary masses, facilitating pericardial aspiration or
transvenous biopsy to obtain material for histology (Andres s et al
1989, Goldfarb et al 1989). Unfortunately, the echocardiographic
features of myocardial infiltration by lymphoma are non-specific
(Balasubramanyam et al 1986); however, radionuclide scans using
67Ga (Constantino et al 1987) and magnetic resonance imaging
(Goldfarb et al 1989) may provide useful diagnostic information.
Treatment includes chemotherapy for the underlying malignant
process combined with anti-failure drugs and pericardial drainage if
required.
1.8 ENDOCARDITIS IN HIV INFECTION
Endocarditis has been found in up to 10% of HIV positive patients




This is the predominant type where non-bacterial, thrombotic
vegetations are found on one or all of the heart valves with the risk
of embolisation into the systemic circulation (Cammarosano and
Lewis 1985, Lopez et al 1987, Lewis 1989). While this may be a
specific complication of HIV, it has also been associated with
wasting illnesses, malignancy and autoimmune disorders (Deppisch
and Fayemi 1976, Livornese and Korzeniowski 1992), all of which
can occur in HIV patients. The signs and symptoms of endocarditis
may be obscured by ongoing HIV disease where fevers and
anaemia are common. The finding of a soft systolic murmur at the
lower left sternal edge, a change in a pre-existing murmur or focal
neurological signs should prompt consideration of the diagnosis.
There is no specific therapy for marantic endocarditis.
1.8.2 Infective endocarditis
This is associated commonly but not exclusively with injection drug
use (Acierno 1989). A range of organisms including bacteria
(Kinney et al 1989) and fungi (Henochowicz et al 1985, Cox et al
1990, Stool et al 1991) can colonise and damage valves,
particularly those on the right side of the heart. Echocardiography
may show vegetations (Henochowicz et al 1985, Kinney et al 1989,
Cox et al 1990) (Figure 1.2). Cox et al (1990) described mobile,
granular masses within the left ventricular cavity at the level of the
insertion of the mitral chordae to the postero-papillary muscle in a
patient with Aspergillus fumigatus endocarditis who subsequently
FIGURE 1.2 Infective endocarditis in HIV infection.
A vegetation is seen on the tricuspid valve (arrow).
RV - right ventricle, LV - left ventricle, RA - right atrium.
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died with widespread mycotic thromboemboli.
Finally, bacteria may colonise the myocardium itself as exemplified
by a case of Staphylococcus aureus abscess formation reported by
Egan et al (1990). Echocardiography showed a lucent area high in
the interventricular septum pointing into the right ventricular
outflow tract. Open heart surgery was performed and effected a
cure although the patient died of opportunistic infection six months
later.
1.9 DISORDERS OF RHYTHM ASSOCIATED WITH HIV
INFECTION
There are four principal causes of rhythm disturbance in HIV
infection - myocarditis and heart muscle disease (Olson et al 1987,
Levy et al 1988, Reilly et al 1988, Levy et al 1989, Lipshultz et al
1989), abnormalities of the conduction system (Bharati and Lev
1989, Bharati et al 1989), derangement of the autonomic nervous
system (Craddock et al 1987, Freeman et al 1990) and side effects
of drug therapy (Wharton et al 1987). Dysrhythmias are
undoubtedly responsible for some cases of sudden death occurring
in HIV positive patients (Levy et al 1988, Reilly et al 1988).
Myocarditis and heart muscle disease in HIV infection are often
complicated by ECG abnormalities and rhythm disturbances
including high grade atrial and ventricular ectopy (Lipshultz et al
1989), ventricular tachycardia (Olson et al 1987, Levy et al 1989)
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and sudden death (Levy et al 1988, Reilly et al 1988). Levy et al
(1988) studied two patients with myocarditis, one of whom died in
the course of an attempted resuscitation from polymorphic
ventricular tachycardia, while the other succumbed to a cardiac
arrest despite the absence of preceding Holter monitor
abnormalities. Similarly, a group of four patients with ventricular
tachycardia - one of which proved fatal - were identified by Reilly
et al (1988), all of whom had myocarditis.
Conduction system abnormalities related to small vessel vasculitis,
fibrosis of neural tissue and myocarditis have been described in
children. These often, but not invariably, give rise to abnormalities
of the ECG and rhythm disturbances (Bharati and Lev 1989,
Bharati et al 1989).
The autonomic nervous system can be damaged by HIV (Freeman
et al 1990). Craddock et al (1987) reported a series of five patients
who sustained syncopal reactions during percutaneous needle
aspiration of the lung. One of these patients subsequently
developed a fatal cardiorespiratory arrest. The clinical features of
these episodes were suggestive of underlying autonomic neuropathy
and indeed, one of these patients and a further four HIV patients
studied had objective evidence of this phenomenon. Dysrhythmias
due to excessive sympathetic tone are also recognised (Lipshultz
1991).
There have been reports of ventricular arrhythmias associated with
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adjuvant therapy for opportunistic infection. Pentamadine, used
widely for the treatment and prophylaxis of Pneumocystis carinii
pneumonia, is structurally similar to procainamide and can cause
ventricular tachycardia, including torsade de pointes (Loescher et al
1987, Wharton et al 1987, Pujol et al 1988, Mitchell et al 1989,
Stein et al 1990). This tendency may be enhanced by concomitant
electrolyte deficiencies, particularly of magnesium (Wharton et al
1987). Patients receiving pentamidine should be monitored for
undue prolongation of the QT interval as a guide to potential
cardiac toxicity. Ganciclovir, an antiviral agent used in the
treatment of cytomegalovirus infection, has also been reported to
provoke ventricular tachydysrhythmias (Cohen et al 1990).
1.10 MYOCARDITIS AND IIIV INFECTION
1.10.1 Diagnosis
Myocarditis is defined histologically using the Dallas Criteria as "a
process characterised by an inflammatory infiltrate of the
myocardium with necrosis and/or degeneration of adjacent
myocytes not typical of the ischaemic damage associated with
coronary artery disease" (Aretz et al 1987). The term "borderline
myocarditis" is used to describe a situation where either myocardial
necrosis or an inflammatory infiltrate is found in isolation (Aretz et
al 1987). The clinical diagnosis of myocarditis requires a high
index of suspicion based upon symptoms and/or compatible
physical findings such as fever, signs of heart failure or a
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praecordial rub. Non-specific ECG changes may occur such as a
sinus tachycardia, conduction defects and repolarisation
abnormalities (Baroldi et al 1988), and there may be radiological
evidence of cardiac enlargement or pulmonary oedema. The
echocardiographic features of myocarditis are non-specific, but
ultrasound examination does have a role as a practical, non-invasive
means of assessing cardiac size and function while also determining
the extent of any associated pericardial effusion. Ultimately,
however, a definitive diagnosis of myocarditis can only be made
histologically. A potential difficulty with HIV infection is that the
associated immune paresis may modify the myocardial
inflammatory response resulting in failure to fulfil the Dallas
criteria thus making the diagnosis impossible without specific
immunohistological stains. The evidence for this comes from a
recent study (Herskowitz et al 1994) which showed that HIV
patients with cardiac failure had specific markers of ongoing
immune mediated heart disease despite complete absence of the
standard histological criteria for myocarditis. This diagnostic
uncertainty may in part explain the wide variation in the reported
prevalence of HIV myocarditis (Table 1.2). While 52% of patients
in one post mortem series had HIV myocarditis (Anderson et al
1988), another study failed to find any myocardial tissue which
fulfilled the Dallas criteria although 5 % of the AIDS patients in this



















































































































































There are no specific echocardiographic features which point
towards a diagnosis of myocarditis. Some groups have
demonstrated dyskinesia of the left ventricle with (Baroldi et al
1988, Levy et al 1988) or without (Lafont et al 1987, Baroldi et al
1988) dilation, or generalised four chamber enlargement (Grange et
al 1990). In one echocardiographic study of patients with
histologically proven myocarditis, wall thickness was found to lie at
the lower end of the normal range (Baroldi et al 1988). Finally,
Lipshultz et al (1989) studied 31 HIV positive children
echocardiographically and showed that hyperdynamic left
ventricular performance was associated with myocarditis. If
ventricular dysfunction is demonstrated, there is a case for
performing a right ventricular endomyocardial biopsy since this
may help to identify infection with opportunistic organsisms such as
Toxoplasma gondii or cytomegalovirus which might respond to
specific antimicrobial therapy. A minimum of five biopsies should
be submitted for light and electron microscopy and viral culture.
Concomitant serology should also be performed in order to try and
establish the presence of secondary infection. Unfortunately,
serological techniques are of limited value in the context of HIV
disease due to widespread immunological dysfunction (Yarchoan
and Broder 1989) which may prevent the development of the usual
pattern of immune responses both to primary and recrudescent
opportunistic infection.
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1.10.3 Myocarditis and HIV heart muscle disease
There is evidence that viral myocarditis can result in idiopathic
dilated cardiomyopathy (Kereiakes and Parmley 1984, MacArthur
et al 1984, Oakley 1990, Richardson and Why 1990). By analogy,
it is likely that a variable proportion of patients with HIV
myocarditis suffer irreversible damage of large numbers of
myocytes resulting in heart muscle disease and progressive cardiac
failure. Thus, myocarditis and heart muscle disease in HIV
infection probably form a continuum of disease. HIV myocarditis
may follow a self-limiting course with just minor constitutional
illness or transient ventricular dysfunction or alternatively progress
to overt, irreversible cardiac failure secondary to heart muscle
disease. The role of myocarditis in the pathogenesis of HIV heart
muscle disease is discussed fully in section 1.11.4.
1.10.4 Aetiology of myocarditis
Myocarditis in HIV infection may be caused by the virus itself,
either directly or indirectly via autoimmune processes, by one of
many opportunistic organisms or by prescribed or illicit drugs
(Acierno 1989, Herskowitz and Baughman 1994).
Cases of myocarditis detected at post mortem where there is no
evidence of secondary infection may represent situations where
HIV is the principal cause of myocyte damage (Anderson et al
1988, Baroldi et al 1988). Direct evidence for the presence of HIV
within the myocardium has been obtained using culture and in situ
hybridisation techniques (Calabrese et al 1987, Flomenbaum et al
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1989, Grody et al 1990, Lipshultz et al 1990, Herskowitz et al
1994). Unfortunately, results based upon culture methods in
particular are potentially misleading because of the possibility of
contamination of cardiac muscle preparations by blood cells
containing HIV. This may explain why Dittrich et al (1988)
detected HIV p24 antigen following co-culture of cardiac myocytes
with phytohaemagglutinin stimulated peripheral blood mononuclear
cells, but failed to confirm the presence of the virus within the
myocardium using immunocytochemistry and in situ hybridisation
with a full length probe.
Even in situ hybridisation may give misleading results as
demonstrated by Grody et al (1990) who found HIV in the hearts of
six out of 22 patients who died of AIDS. They admitted that the
strength and intensity of the hybridisation signal tended at times to
obscure the morphology of the positive cells, making precise
identification of the target difficult.
The absence of CD4 receptors in cardiac tissue (Grody et al 1990)
and the results of in vivo experiments which have shown that HIV
is unable to gain entry into skeletal muscle cells (Trujillo et al
1991) appear to militate against primary HIV myocarditis. It is
recognised, however, that CD4 receptors are not always essential
since HIV has been found in tissues where such receptors are
absent including colonic cancer cells (Heyworth et al 1991), nerve
and liver cells (Levy 1990). The Fc and complement receptors
may be more important than CD4 in allowing HIV to enter cells
26
(Levy 1993, Herskowitz et al 1993b). Finally, HIV might induce
myocarditis by residing in the supporting cells of the myocardium
such as interstitial dendritic and endothelial cells (Herskowitz et al
1993b) rather than in the myocytes themselves.
The apparent inconsistency of results and the paucity of published
material detailing the direct effects of HIV on the myocardium
mean that the role of primary HIV infection in the pathogenesis of
myocarditis is still a matter of speculation.
Similarly, the pathogenetic mechanisms which may be responsible
for myocarditis due solely to HIV have not been established
although a number of theories have been proposed. HIV may enter
cardiac myocytes and cause damage either as it replicates (Acierno
1989) or through a non-specific inflammatory response (Herskowitz
et al 1993b). Alternatively, by analogy with T helper lymphocytes,
an intrinsic cellular process may be initiated by the virus leading to
apoptosis (Moore and Blanc 1991, Dalgleish and Colizzi 1992,
Ameisen 1994).
HIV induced myocyte damage might also occur indirectly through
three distinct autoimmune mechanisms. Herskowitz et al (1990b)
found high levels of circulating cardiac autoantibodies in HIV
patients with myocarditis and heart muscle disease. It is possible
that HIV enters myocytes and either modifies existing surface
antigens or exposes previously hidden epitopes provoking the
immune system to generate anti-heart antibodies.
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More recent results from the same group (Herskowitz et al 1994)
indicate that there is a significant increase in class I major
histocompatibility complex antigen expression on myocytes from
HIV positive patients with myocarditis compared with seronegative
controls also suffering from myocarditis. Moreover, the HIV
positive patients have a marked excess of infiltrating CD8 cells
within the myocardium compared with their controls. Given that
class I major histocompatibility complex antigen expression does
not normally occur in cardiac myocytes (Herskowitz et al 1990a), it
has been postulated that HIV (either singly or in combination with
another infectious agent such as cytomegalovirus) may induce
myocyte expression of these antigens which are then targeted by
CD8 lymphocytes resulting in cell damage.
Another possible mechanism of autoimmune myocyte damage is the
"innocent bystander" effect which was proposed by Ho et al (1987)
to explain central nervous system destruction in HIV infection.
According to this hypothesis, tissue which is not itself infected with
HIV is invaded by immunocytes containing the virus. These cells
release proteolytic enzymes as they die causing local damage.
Lymphokines are also released which promote further ingress of
immunocompetent cells which in turn augment the process of tissue
destruction. In this way, a minority cell population infected by
HIV causes a cascade reaction which destroys surrounding
non-infected tissue. Lymphokines such as tumour necrosis factor
have indeed been demonstrated in abnormally high concentrations
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in the blood of patients with HIV infection (Lahdevirta et al 1988)
and have also been shown to cause skeletal myocyte death in vitro
(Trujillo et al 1991). Finally, high plasma interleukin-6
concentrations have been found in HIV patients with heart muscle
disease (Herskowitz et al 1993b).
Many opportunistic agents are associated with myocarditis in HIV
infection including Toxoplasma gondii (Roldan et al 1987, Lafont et
al 1988, Vynn Adair et al 1989, Hofman et al 1991),
cytomegalovirus (Lafont et al 1988), Cryptococcus neoformans
(Cammarosano and Lewis 1985, Lewis et al 1985, Roldan et al
1987), Histoplasma capsulatum (Lafont et al 1988) and Aspergillus
fumigatus (Cox et al 1990). New infectious co-factors continue to
be identified. In particular, several mycoplasma species have been
implicated in the pathogenesis of HIV damage to the kidney, liver
and spleen (Anonymous - Lancet editorial 1991a). These diverse
organisms might cause myocyte damage through the same
mechanisms as HIV or by synergism with the virus (Dittrich et al
1988, Nelson et al 1990).
Myocarditis caused by Toxoplasma gondii has been treated
successfully with antibiotics (Grange et al 1990) while that
associated with HIV per se has been shown to respond to
immunosuppressants (Levy et al 1988, Herskowitz and Baughman
1994). However, it is impossible to be certain if any improvement
in cardiac function with such therapies represent a genuine response
to treatment or merely part of the natural history of a potentially
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self-limiting condition.
1.11 HIV HEART MUSCLE DISEASE
1.11.1 Background
The first report of heart muscle disease associated with HIV
infection was published in 1986. Cohen et al (1986) described
three HIV positive patients who presented with the symptoms and
signs of heart failure. Two of the three patients underwent post
mortem examinations which showed global dilation of the cardiac
chambers without evidence of coronary artery disease or
myocarditis. Since then, a number of in vivo studies (Fink et al
1984, Cohen et al 1986, Steinhertz et al 1986, Corboy et al 1987,
Corallo et al 1988, Raffanti et al 1988, Himelman et al 1989a,
Levy et al 1989, Lipshultz et al 1989, Stewart et al 1989,
Blanchard et al 1991, Herskowitz et al 1993a) and retrospective
post mortem analyses (Anderson et al 1988, Joshi et al 1988, Lewis
1989) have confirmed the existence of "HIV heart muscle disease"
(Table 1.3). This term is preferable to "HIV cardiomyopathy"
since by definition, cardiomyopathy occurs in the absence of a
known causative agent (Report of the WHO/ISFC Task Force
1980). Estimates of the prevalence of HIV heart muscle disease
vary widely with one group (Corallo et al 1988) reporting that 41 %
of their patients had left ventricular dysfunction while another
(Lewis 1989) showed that only 2% had cardiac dilation at post
mortem. Herskowitz et al (1993) analysed six echocardiographic
studies involving a total of 450 HIV infected patients. They showed
30
that between 3% and 41% (mean 17.5%) had left ventricular
hypokinesia and that 6.2% had or developed congestive cardiac
failure. The consensus of published reports is that it occurs in all
major risk groups including homosexuals (Fink et al 1984, Corboy
et al 1987, Himelman et al 1989a, Lewis et al 1989, Blanchard et al
1991), injection drug users (Corallo et al 1988, Raffanti et al 1988)
and children (Steinhertz et al 1986, Joshi et al 1988, Lipshultz et al
1989, Stewart et al 1989), being manifest particularly (Monsuez et
al 1988, Himelman et al 1989a, Levy et al 1989, Herskowitz et al
1993a), but not exclusively (Blanchard et al 1991), in late stage
disease.
The evidence that heart muscle disease represents a specific
phenomenon associated with HIV infection as opposed either to a
non-specific manifestation of chronic disease in a dying patient or
to injection drug use per se is based on a number of observations.
Firstly, cardiac dysfunction has been documented in apparently
healthy, well nourished patients (Levy et al 1989). Secondly,
Himelman et al (1989a) studied 70 ambulant and hospitalised HIV
patients and compared them to 20 inpatients with acute leukaemia.
The hospitalised patients with HIV had more advanced disease than
their ambulant counterparts and were of similar nutritional status to
those with leukaemia, as evidenced by per cent of predicted ideal
body weight and serum albumin. Eight patients with heart muscle
disease were identified on the basis of echocardiograms showing
four chamber enlargement and diffuse left ventricular hypokinesia.
All eight were HIV positive and hospitalised, and remarkably, four
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of them had the diagnosis of heart muscle disease made only at the
time of their ultrasound study. None of the leukaemic patients,
despite their parlous condition, had evidence of myocardial
dysfunction. Within six months, four of the eight patients had
died, indicating that the presence of cardiac dysfunction in late
stage HIV infection was a particularly poor prognostic factor.
Finally, Willoughby et al (1993) prospectively studied 86 HIV
negative injection drug users in the Baltimore area and found just
one patient with asymptomatic, mild left ventricular dysfunction.
This compared to a remarkable 21 out of 69 patients in a similar
study of an age matched cohort of injection drug users who were
HIV positive.
HIV heart muscle disease can cause dilation and dysfunction of one
or both ventricles. Some cases of isolated right ventricular
dysfunction may, however, arise from pressure or volume
overload. Disease of the right ventricle will therefore be discussed
separately.
1.11.2 Left and biventricular HIV heart muscle disease
This is the most clinically significant form of HIV heart muscle
disease and may cause symptoms such as fatigue, breathlessness
and palpitations together with physical signs of heart failure
including resting tachycardia, elevated jugular venous pressure,
gallop rhythm, basal crackles and peripheral oedema. Table 1.3
lists the most significant studies of this condition.
TABLE 1.3 STUDIES OF HEART MUSCLE DISEASE IN HIV INFECTION
Authors No. of Type of Risk Group Stage of Percentage
Patients Study Disease with HM)^
Comment
Anderson et a I 1988 71 Autopsy 75% AIDS 7 (10%)
Homosexual
All had myocarditis.
Blanchard et al 1991 70 Echo 99% Mixed 8 (11%)
Homosexual
All asymptomatic.
Corallo et al 1988 102 Echo + 70% IDU AIDS 42 (41%)
Autopsy
None had overt signs
of LVF^. True and
borderline myocarditis
at autopsy.
Fink et a I 1984 15 Echo + 80% AIDS 3 (20%)
Autopsy Homosexual
Herskowitz et al 1993a 69 Echo 36% IDU Mixed 10 (14%) All asymptomatic.




patients being in hospital.
Levy et a I 1989 60 Echo 98% Mixed 14 (23%)
Homosexual
Lewis 1989 115 Autopsy AIDS 2 (2%)




signs. Some had myo¬
carditis.
Monsuez et a I 1988 86 Echo 40% AIDS + 13 (15%) 7 had no clinically
4
Homosexual ARC apparent heart disease.
Raffanti et a I 1988 12 RNV + 75% IDU AIDS 2 (17%) Both asymptomatic. No
Autopsy clinical signs of LVF.
ReiIly et al 1988 58 RNV + 91% AIDS 4 (7%) All had myocarditis.
Autopsy Homosexual
1 - heart muscle disease 2 - injection drug user 3 - left ventricular failure
4 - AIDS related complex 5 - radionuclide ventriculography
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In one of the most comprehensive echocardiographic studies to
date, Corallo et al (1988) evaluated 102 patients with late stage
HIV disease, the majority of whom were injection drug users.
Forty-two patients had a globular left ventricle with diffuse
reduction of wall motion. These features were particularly marked
in patients with terminal HIV disease and were usually
accompanied by a mild to moderate pericardial effusion.
Stewart et al (1989) evaluated a group of eight children who had
been referred because of respiratory difficulties. In no case had a
cardiac diagnosis been considered. All the children suffered from
chronic pulmonary infections and were found to have
hepatosplenomegaly, tachypnoea and tachycardia.
Echocardiography showed a reduced left ventricular shortening
fraction in every case. This was accompanied by concentric left
ventricular hypertrophy in three patients and dilation of the left
ventricle in five. One child had biventricular dilation and
hypofunction and three other patients had associated pericardial
effusions.
A more recent study of 70 patients, mainly homosexuals, identified
eight individuals with left ventricular dysfunction (ejection fraction
below 45% and/or fractional shortening less than 28%), three of
whom reverted to normal on subsequent examination (Blanchard et
al 1991). Persistent left ventricular dysfunction appeared to carry a
poor prognosis.
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Finally, Herskowitz et al (1993a) recorded a 14.5% prevalence of
global left ventricular hypokinesia in a group of 69 HIV positive
non-AIDS patients. This group was studied prospectively for a
mean of 11 months and the incidence of left ventricular dysfunction
was found to be 18% per patient-year.
Isolated left ventricular dilation has been reported by some workers
(Levy et al 1989, Flavia et al 1991) and this may progress to severe
biventricular failure (Flavia et al 1991).
Treatment is undertaken with conventional agents including
diuretics, digoxin, inotropes, and vasodilators (Steinhertz et al
1986, Stewart et al 1989). Where there is associated myocarditis,
high dose prednisolone may be of benefit (Herskowitz and
Baughman 1994). Some workers have used serial
echocardiography to demonstrate improvements in cardiac function
(Blanchard et al 1991, Herskowitz et al 1992). Regrettably,
however, even where there is improvement in the symptoms and
signs of heart failure, this is often short lived, with patients dying
of either progressive heart failure (Cohen et al 1986, Himelman et
al 1989) or impairment of other organ systems (Himelman et al
1989, Stewart et al 1989). Persistent echocardiographic evidence of
left ventricular dysfunction (Blanchard et al 1991) and clinically
overt heart failure (Monsuez et al 1988) are poor prognostic
indicators.
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1.11.3 Aetiology ofHIV heart muscle disease
The aetiology of HIV heart muscle disease is unknown,
undoubtedly complex and probably multifactorial. The most likely
causative factors are preceding myocarditis attributable either to
HIV itself or secondary infectious agents (see Section 1.10),
nutritional deficiencies, the effects of drugs used in the treatment of
HIV disease and its complications and possibly also excessive
sympathetic drive (Acierno 1989, Herskowitz and Baughman
1994). Injection drug use per se may account for a very small
proportion of heart muscle disease cases in this subgroup of HIV
positive patients (Herskowitz and Baughman 1994).
1.11.4 Myocarditis and HIV heart muscle disease
The hypothesis that heart muscle disease is caused by preceding
myocarditis is supported firstly by post mortem studies which have
demonstrated myocarditis in hearts with structural disease (Cohen
et al 1986, Anderson et al 1988, Corallo et al 1988) and secondly
by analogy with idiopathic dilated cardiomyopathy. Finally, the
recent demonstration that some cases of left ventricular dysfunction
in patients with HIV infection resolve spontaneously (Blanchard et
al 1991) is also consistent with the idea that myocarditis, which is
potentially self-limiting, serves as the substrate for the subsequent
development of HIV heart muscle disease.
The reported prevalence of myocarditis associated with HIV heart
muscle disease varies widely (see Table 1.2) possibly as a result of
a combination of sampling errors, failure to use standard diagnostic
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criteria, the transient nature of the underlying inflammatory
processes and the difficulty of applying the Dallas criteria in a
condition where the capacity to mount an immune response is
impaired (Yarchoan and Broder 1989, Herskowitz et al 1994).
There have been three major studies where attempts have been
made to correlate clinical, echocardiographic or post mortem signs
of heart muscle disease with histological evidence of myocarditis as
defined by the Dallas criteria.
Anderson et al (1988) evaluated retrospectively autopsies of 71
patients who had died of AIDS. Ten cases of biventricular dilation
were found and all these patients had myocarditis. However, a
further 27 patients also had myocarditis, five of whom had
evidence of myocardial infection by opportunistic pathogens.
A similar study was performed by Baroldi et al (1988). Here, ante
mortem echocardiography was performed in eight patients, six of
whom were found to have left ventricular dysfunction. Four of
these six patients had myocarditis and the remaining two had
borderline myocarditis. The two patients with normal
echocardiograms had no lymphocytic infiltrates within their hearts.
Again, five other patients with myocarditis had no macroscopic
evidence of heart muscle disease.
The third study (Reilly et al 1988) showed that AIDS patients with
ventricular tachycardia, congestive cardiac failure and/or a left
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ventricular ejection fraction of 44% or less using radionuclide
ventriculography invariably had myocarditis at post mortem. As a
group, patients with myocarditis had a significantly higher
incidence of serious cardiac abnormalities compared with those
with normal histology.
HIV heart muscle disease can be likened to idiopathic dilated
cardiomyopathy, a condition that may also have a viral aetiology
(Kereiakes and Parmley 1984, MacArthur et al 1984, Richardson
and Why 1990). Here, there is considerable experimental evidence
based upon human, animal and in vitro work of the pathogenetic
role of myocarditis (Kereiakes and Parmley 1984, MacArthur et al
1984, Oakley 1990, Richardson and Why 1990).
In contrast to idiopathic dilated cardiomyopathy, however,
evaluation of the pathogenetic role of preceding myocarditis and the
natural history of HIV heart muscle disease will be potentially
easier to perform. This is because firstly HIV heart muscle disease
occurs in a well defined group of patients and secondly the
responsible virus and its antigens have been characterised. Work in
this field may therefore not only help to increase our understanding
of the pathogenesis of both conditions but also lead potentially to
new forms of treatment. For example, identification of the
immunological mediators of heart muscle damage may permit the
development of specific therapy such as monoclonal antibodies
directed against cardiotoxic effector cells and their release products
(Wolff 1991).
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1.11.5 Nutritional deficiencies and HIV heart muscle disease
There is increasing interest in the nutritional deficiencies which
occur in HIV infection as a result of reduced intake and
malabsorption (Kotler 1989, Anonymous - Lancet editorial 1991b).
These include, inter alia, B group vitamins, zinc, folate and
selenium (Dworkin et al 1986, Baum et al 1991a, Baum et al
1991b, Beach et al 1991, Mantero-Atienza et al 1991). Some of
these deficiencies may be mediated by tumour necrosis factor
(Beutler 1988), a cytokine which has been implicated in cellular
damage caused by HIV (Beutler 1988, Trujillo et al 1991).
Deficiencies of zinc and some B group vitamins have been
associated with reversible impairment of immune function (Baum et
al 1991a, Baum et al 1991b, Beach et al 1991), a factor which may
influence the inflammatory mechanisms underlying the
development of myocarditis and heart muscle disease.
Recently, it has been reported that excessive amounts of the
products of oxidative metabolism have been found in the blood of
HIV positive patients (Fuchs et al 1991). This may reflect a defect
in naturally occurring antioxidant systems of which the
selenoenzyme glutathione peroxidase is an integral part. A form of
cardiomyopathy known as Keshan disease occurs endemically in a
Chinese province and its incidence has been reduced by widespread
dietary supplementation with selenium (Keshan Disease Research
Group 1979). Similarly, a relationship between selenium deficiency
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and the development of potentially reversible HIV heart muscle
disease has been observed in a small group of HIV patients (Zazzo
et al 1988), but this requires formal assessment. The link between
selenium deficiency and HIV heart muscle disease are discussed
comprehensively in Chapter 6.
1.11.6 Zidovudine and HIV heart muscle disease
Some drugs used in the treatment of HIV disease and opportunistic
infection may be cardiotoxic. Zidovudine is a thiamidine analogue
which, by interfering with HIV RNA dependent DNA polymerase
(reverse transcriptase), inhibits elongation of the viral DNA chain
and reduces viral replication (Fischl 1989). It is now widely used in
HIV infection and among its recognised side effects is inhibition of
mitochondrial DNA replication (Arnaudo 1991) which can cause or
exacerbate a skeletal myopathy characterised by pain, weakness and
wasting (Fischl 1989, Berger et al 1991). This is dose dependent,
associated with long term therapy (Fischl 1989) and potentially
reversible (Berger et al 1991). Characteristic histological changes
are found in skeletal muscle including focal necrosis, "ragged red"
sarcoplasm, mitochondrial abnormalities and numerous cytoplasmic
bodies (Fischl 1989) (Figure 1.3). Histological abnormalities
improve when zidovudine is discontinued (Dalakas et al 1990)
(Figure 1.4). Similar features have been noted in the cardiac
muscle of rats given zidovudine (Lamperth and Dalakas 1991).
Myopathy may be mediated by mitochondrial damage (Peters et al
1993). To date, there is only limited anecdotal evidence
implicating zidovudine in the pathogenesis of HIV heart muscle
A
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FIGURE 1.3 Histology of muscle biopsy specimen from a
patient with zidovudine-associated myopathy.
In Panel A, two ragged-red fibres can be seen in a transverse
frozen section stained with the modified Gomori trichrome
stain; a large number of such fibres were noted throughout the
specimen (x685). In Panel B, abnormal mitochondria with
paracrystalline inclusions (arrows) are evident in an electron
micrograph (x8820).
(Reproduced from Dalakas et al, N Engl J Med 1990;322:1098-
1105).
B
FIGURE 1.4 Reversibility of zidovudine-associated myopathy.
Panel A shows extensive muscle fibre destruction due to
zidovudine therapy (modified Gomori trichrome stain x85).
Panel B shows a frozen section taken from the same muscle four
months after discontinuation of zidovudine therapy (modified
Gomori trichrome stain x80). There is marked improvement in
the muscle fibre cyto-architecture).
(Reproduced from Dalakas et al, N Eng J Med 1990;322:1098-
1105).
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disease in man. Herskowitz et al (1992) studied 26 HIV infected
patients with congestive cardiac failure and showed that three
individuals developed cardiac dysfunction during treatment with
zidovudine which resolved following its discontinuation. The
potential role of zidovudine in the pathogenesis of HIV heart
muscle disease is discussed in Chapter 4.
1.11.7 The autonomic nervous system and HIV heart muscle
disease
Heart muscle disease may also occur as a result of excessive
sympathetic stimulation in a manner analogous to cardiac damage
caused by the high circulating level of catecholamines in
phaeochromocytoma (Sardesai et al 1990). Excessive activation of
the sympathetic system may be caused by autonomic imbalance
related to HIV damage of neural pathways (Freeman et al 1990) or
by stimulation of beta receptors by the group 120 protein (Glulio et
al 1991).
1.12 ISOLATED RIGHT VENTRICULAR DILATION AND
HIV INFECTION
Radionuclide (Raffanti 1988) and echocardiographic (Himelman et
al 1989b, Stewart et al 1989, Blanchard et al 1991) studies have
shown that right ventricular abnormalities are common in HIV
infection and may be transient (Kavanaugh-McHugh et al 1991).
Dilation and dysfunction of the right ventricle may occur as part of
a global myopathic process, characterised echocardiographically by
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four chamber dilation and loss of function (Cohen et al 1986,
Corboy et al 1987, Himelman et al 1989a, Stewart et al 1989)
through mechanisms which have already been discussed. However,
some cases are related not to intrinsic disease of the heart muscle
but rather to the effects of a pressure or volume load.
Recurrent respiratory infections, a problem almost universal in HIV
positive patients, can cause pulmonary hypertension and right
ventricular failure (Himelman et al 1989b). Indeed, cor pulmonale
has been reported as the index diagnosis of congenital AIDS on at
least one occasion (Hays et al 1991). Right ventricular
abnormalities associated with respiratory infection are potentially
reversible with antibiotic therapy (Blanchard et al 1991).
Increased right heart pressure may also arise secondary to emboli
impacting in the pulmonary microvasculature following the
administration of particulate matter during injection drug use
(Himelman et al 1989b) or through necrotising angiitis (Citron et al
1970).
Finally, Coplan et al (1990) have reported four patients who
presented with pulmonary hypertension attributable solely to HIV
induced pulmonary arteritis.
In the largest study to date evaluating isolated right ventricular
disease in AIDS, Himelman et al (1989b) described six men
presenting predominantly with progressive exertional dyspnoea, all
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of whom had ECG evidence of right ventricular hypertrophy.
Doppler echocardiography demonstrated right atrial and ventricular
enlargement, paradoxical septal motion and marked elevation in
right ventricular systolic pressure. Cardiac catheterisation
confirmed that pulmonary artery and right heart pressures were
elevated as was the pulmonary vascular resistance. Left ventricular
filling pressure and cardiac output were in the low to normal range.
These findings occurred in the context of pulmonary infection in
five of the six patients. The sixth patient, however, was found to
have abnormalities consistent with multiple emboli on selective
pulmonary angiography and was treated with oral anticoagulants.
Endocarditis causing damage and dysfunction of the tricuspid valve
is also potentially capable of causing right ventricular dilation as a
result of excessive volume load. Such a case associated with
marantic endocarditis was described by Fink et al (1984).
However, tricuspid valve incompetence does not always imply
preceding endocarditis since it may be the consequence rather than
the cause of right ventricular dilation.
1.13 HIV INFECTION IN EDINBURGH
The nature of the outbreak of HIV infection in Edinburgh provides
a unique opportunity to study the natural history of heart muscle
disease associated with this condition.
HIV was introduced into the city in the early 1980's and its rapid
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spread through the injection drug user population was facilitated by
widespread needle sharing which flourished as a result of a
clampdown on drug addiction by the police. So called "shooting
galleries" sprang up in several of the city's peripheral local
authority housing estates where the virus spread with alarming
speed (Brettle 1990). Thus, in the period 1982-5, up to 51% of
heroin injectors in Edinburgh were found to be HIV positive
(Davies et al 1994) in contrast to just 3.4% of a comparable group
in Glasgow sampled in 1986 (Taylor et al 1994).
By December 1991, 913 people in Lothian had been infected with
HIV, 53% having contracted the virus through injection drug use
(The Reid Report March 1993). The unpublished figures for the
period ending March 1993 are 960 and 54% respectively (Bath,
HIV/AIDS and Drugs Team - personal communication).
Subsequently, there has been a concerted effort by health care and
social work agencies to reduce the extent of HIV infection,
particularly amongst injection drug users. This carries particular
urgency since the majority are heterosexual and therefore have the
potential to infect their partners and children. Risk reduction
strategies include the promotion of oral heroin substitutes such as
methadone, the provision of clean needles and syringes,
encouragement to use freely supplied condoms and, most
importantly, the fostering of an awareness of HIV infection. As a
result, the prevalence of HIV infection amongst injection drug users
in Glasgow has fallen to 1% (Taylor et al 1994) while Edinburgh
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has witnessed a dramatic decline from 51% to 20.4% (Davies et al
1994).
In Edinburgh, the vast majority of HIV patients in all risk groups
undergo regular medical review at the City Hospital infectious
diseases clinic. A small number of patients (predominantly
homosexuals) also attend the genito-urinary department of the
Royal Infirmary. Despite the pessimism concerning the ability to
follow up injection drug users, the City Hospital default rate is only
around 20% (Brettle et al 1994). Smaller clinics are also conducted
near the housing estates where many of the target population live.
In addition, inmates at the local prison are offered a comprehensive
medical service including confidential HIV testing and treatment
with oral methadone.
Thus, not only is there a disproportionately large HIV population in
Edinburgh, but the experience has been carefully documented and a
vast amount of epidemiological, clinical and immunological data is
now available. This is coupled with a comprehensive library of
serum and lymphocyte samples obtained at outpatient clinics and
tissue from all parts of the body collected at post mortem. This
material is available for retrospective analysis using techniques
including in situ hybridisation and the polymerase chain reaction.
Another factor which makes Edinburgh a unique setting in which to
study the natural history of HIV heart muscle disease is the
projected steep rise in the number of late stage victims of HIV
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infection - patients that are most likely to develop ventricular
dysfunction. It is estimated that in 1995 the Lothians will contain
the majority of new cases of AIDS in Scotland (80 out of 145).
This is based upon the fact that this region has currently both the
highest number and proportion of individuals with CD4 counts of
200 or less (The Reid Report March 1993).
1.14 CURRENT ISSUES RELATING TO THE NATURAL
HISTORY OF AND PATHOGENETIC LINKS BETWEEN
HIV AND HEART MUSCLE DISEASE
To date, most studies of cardiac dysfunction in HIV disease have
been based on small series or isolated case reports, predominantly
from America. Most individuals studied belong to one risk group -
usually homosexuals - and their findings may not be representative
of the generality of patients with HIV infection. In particular, the
general health and nutritional status of injection drug users will be
poor compared with homosexuals and these disadvantages may
increase their risk of developing end-organ damage including heart
muscle disease.
The paucity of large, longitudinal series in the world literature has
resulted in a failure firstly to establish the true incidence and
secondly to determine the natural history of the various forms of
heart muscle disease. This information can be gleaned only from a
large, prospective study involving patients drawn from all the risk
groups for HIV infection. Such a study may also help to determine
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whether the various forms of HIV heart muscle disease are
potentially reversible and also establish their prognostic
significance.
The precise aetiology of HIV heart muscle disease remains
obscure. Undoubtedly a multiplicity of factors operate either singly
or in combination.
If direct involvement of the virus is important, is there evidence
that HIV can enter the myocardium given that results to date are
contradictory? Does the virus exert its deleterious effects directly
through replication and cell death, or indirectly through
immunological mechanisms?
Is there a role for opportunistic infection in the pathogenesis of
HIV heart muscle disease? Case reports based upon in situ
hybridisation, the polymerase chain reaction, electron microscopy
and serological techniques have demonstrated organisms such as
cytomegalovirus, Toxoplasma gondii and coxsackie virus associated
with myocarditis and heart muscle disease. However, no causative
link has yet been found.
Given the widespread use of zidovudine and the anecdotal reports
in the literature of improvement in cardiac function when the drug
is discontinued, it is necessary to establish whether this agent does
indeed exert a harmful effect on the myocardium.
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Finally, a wide variety of nutritional deficiencies have been
reported in HIV patients and there is limited evidence that the
administration of selenium may enhance cardiac function.
Confirmation that HIV heart muscle disease is related to selenium
or some other deficiency state may therefore be of major
therapeutic importance since, by analogy with Keshan disease,
dietary supplements could be offered to patients in the early stages
of HIV infection by way of prophylaxis. Moreover, such therapy
may actually improve cardiac function in some individuals with
established heart muscle disease.
APPENDIX 1
CLINICAL CATEGORIES OF HIV INFECTION
Table 1.1 gives the 1993 revised classification system for HIV
infection and AIDS for adolescents and adults (Morbidity and
Mortality Weekly Report 1993). The clinical categories upon which
the classification system is based are defined as follows:
Category A
Category A consists of one or more of the conditions listed below
in an adolescent or adult (>13 years) with documented HIV




Acute (primary) HIV infection with accompanying
illness or history of acute HIV infection
Category B
Category B consists of symptomatic conditions in an HIV infected
adolescent or adult that are not included among conditions listed in
clinical Category C and that meet at least one of the following
criteria: a) the conditions are attributed to HIV infection or are
indicative of a defect in cell-mediated immunity; or b) the
conditions are considered by physicians to have a clinical course or
to require management that is complicated by HIV infection.




Candidiasis, vulvovaginal; persistent, frequent, or poorly
responsive to therapy
Cervical dysplasia (moderate or severe)/cervical carcinoma
in situ
Constitutional symptoms, such as fever (38.5°C) or diarrhoea
lasting > 1 month
Hairy leukoplakia, oral
Herpes zoster (shingles), involving at least two distinct
episodes or more than one dermatome
Idiopathic thrombocytopenic purpura
Listeriosis




Category C includes the clinical conditions listed in the AIDS
surveillance case definition. These comprise -
a) certain specified secondary infectious diseases:
Pneumocystis carinii pneumonia, chronic cryptosporidiosis,
toxoplasmosis, extra-intestinal strongyloidiasis, isosporiasis,
candidiasis (oesophageal, bronchial or pulmonary),
cryptococcosis, histoplasmosis, mycobacterial infection with
Mycobacterium avium complex or M kansasii, pulmonary
tuberculosis, recurrent pneumonia, cytomegalovirus
infection, chronic mucocutaneous or disseminated herpes
simplex virus infection and progressive multifocal
leukoencephalopathy;
b) secondary cancers which are at least moderately indicative
of a defect in cell-mediated immunity:
Burkitt's tumour or lymphoma, immunoblastic sarcoma,
Kaposi's sarcoma, histiocytic lymphoma, large cell
lymphoma, primary lymphoma of the brain, reticulosarcoma




The aims of this thesis are to establish the natural history of HIV
related heart muscle disease and investigate its aetiology.
A cohort of 240 HIV patients underwent a prospective
echocardiographic study in order to define the nature and extent of
heart muscle disease in a representative population drawn from all
adult risk groups - injection drug users, homosexuals,
haemophiliacs and heterosexuals. Serial ultrasound examinations
were performed in an attempt firstly to determine the event rate,
including the incidence of new cardiac abnormalities, and secondly
to assess whether each of the various forms of heart muscle disease
was progressive or reversible.
Although many of these individuals were initially asymptomatic,
serial CD4 counts (an indicator of the progression of HIV infection)
indicated that a significant proportion would develop clinical
manifestations of the disease during the next few years. Blood was
drawn regularly as part of the routine clinical evaluation and
samples were stored at -70°C for future analysis. An agreement
with the Edinburgh University Department of Pathology ensured
that patients subjected to post mortem examination had samples of
cardiac tissue retained. This was supplemented by tissue obtained
using endomyocardial biopsy in those patients in whom it was felt
necessary to try and exclude myocarditis attributable to potentially
treatable opportunistic pathogens.
In this way, a substantial echocardiographic and tissue database was
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established making it possible to correlate the presence or
development of heart muscle disease with existing background
information.
Chapter 3 describes the results of the echocardiographic study and
includes an assessment of whether the various forms of heart
muscle disease were progressive or reversible.
Chapter 4 examines the pathological significance firstly of
opportunistic infection with cytomegalovirus and Toxoplasma
gondii and secondly of treatment with zidovudine in the
development of HIV heart muscle disease.
Chapter 5 explores the role of direct HIV infiltration of the
myocardium. Patients with heart muscle disease had samples of
cardiac tissue analysed for the presence of HIV using the
polymerase chain reaction. Immunohistochemical techniques with
antibodies directed against the p24 and group 120 antigens were
employed to look for evidence of viral replication.
Chapter 6 describes the potential aetiological significance of
selenium deficiency in the development of HIV heart muscle
disease. This was based upon the findings in a sub-cohort of HIV
patients with cardiac dysfunction who underwent assay of serum
selenium. A similar assay was performed in HIV positive controls
matched for age, sex, risk group, body mass index and stage of
disease.
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Chapter 7 illustrates the prognostic implications and the effects
upon overall survival of the various forms of HIV heart muscle
disease.
Each chapter is set out in the form of a brief introduction followed
by methodology and results and finally a discussion.
Chapter 8 summarises the key findings and indicates areas where
further research effort may be directed.
CHAPTER 3
AN ECHOCARDIOGRAPHY STUDY OF
HIY HEART MUSCLE DISEASE
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3.1 SUMMARY
A prospective echocardiographic study was undertaken in order to
assess the prevalence, event rate and reversibility of heart muscle
disease associated with HIV infection. Patients from all major risk
groups (injection drug users, homosexuals, heterosexuals and
haemophiliacs) were studied.
Abnormalities were detected in the index echocardiograms of 34
out of 240 patients, giving a prevalence of 14.2%. These took one
of three forms. (1) Dilated cardiomyopathy was found in 13
patients (eight homosexuals, three injection drug users and two
haemophiliacs). (2) Borderline left ventricular dysfunction was
found in 12 patients (10 injection drug users and two homosexuals)
and (3) Isolated right ventricular dilation was detected in nine
patients (eight injection drug users and one heterosexual).
Patients with dilated cardiomyopathy were invariably in CDC
group IV, indicating late stage HIV disease. This was confirmed
by their median CD4 count which at 10 cells/yu.1, was significantly
lower than that of individuals with other forms of heart muscle
disease and also those with structurally normal hearts.
Homosexuals were disproportionately represented in the dilated
cardiomyopathy group, probably because they had more advanced
HIV disease.
A total of 198 additional echocardiograms were performed in 115
53
patients including 23 with heart muscle disease - seven with dilated
cardiomyopathy, eight with borderline left ventricular dysfunction
and eight with isolated right ventricular dilation. There was no
improvement in cardiac function in patients with dilated
cardiomyopathy. However, two out of eight patients in the
borderline left ventricular dysfunction group reverted to normal as
did five out of eight individuals with isolated right ventricular
dilation. Most of the patients with reversible isolated right
ventricular dilation had a chest infection at the time of their index
echocardiogram and two out of three individuals with a persistent
abnormality of the right ventricle had primary mechanical causes to
account for this. Among the 92 patients with normal index
echocardiograms, four subsequently developed heart muscle disease
over a period of 94.6 patient-years giving an event rate of 4.23%
per patient-year.
Heart muscle disease occurs commonly in HIV infected patients
and takes a number of different forms. Dilated cardiomyopathy is
a feature of advanced HIV disease, affects all the major risk groups
for HIV infection and does not appear to be reversible. In contrast,
borderline left ventricular dysfunction and isolated dilation of the
right ventricle occur at an earlier stage of HIV infection and may
be evanescent. This suggests that they may arise secondary to




Dilation and dysfunction of one or both ventricles may occur in
HIV infection (Acierno 1989, Herskowitz and Baughman 1994).
Several cross-sectional surveys, predominantly from the USA have
described HIV heart muscle disease in patients belonging to one or
other risk group (see Section 1.11). However, little attention has
been paid to either the event rate (incidence) or the potential
reversibility of the various forms of heart muscle disease and there
have been very few studies of patients infected with HIV in
Europe.
A total of 240 patients drawn from all the major risk groups for
HIV infection were examined in a prospective echocardiographic
study in order to establish the prevalence and event rate of heart
muscle disease and determine also whether the various forms of
cardiac dysfunction were progressive or reversible.
The prognostic implications of HIV heart muscle disease are
described in Chapter 7.
3.3 PATIENTS AND METHODS
3.3.1 Patients
Outpatients were recruited mainly from the HIV clinic at the City
Hospital with a small contribution from the Genito-Urinary
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Department and Haemophilia Centre at the Royal Infirmary.
There was no formal selection process but in general, regular
attenders with CD4 counts of less than 200 cells//d were asked to
participate after giving informed consent. This value for CD4 was
chosen as it had been shown (see Table 1.3) that cardiac
abnormalities occur predominantly in people with late stage HIV
disease. Injection drug users were more likely to reject the offer of
echocardiographic screening while homosexuals usually gave their
consent freely.
Inpatients at both hospitals were also studied. Among the most
common reasons for admission were chest infections (including
Pneumocystis carinii pneumonia), end-organ disease such as HIV
encephalitis, cytomegalovirus retinitis and vacuolar myelopathy,
and psychosocial problems. Similar entry criteria applied, but a
greater proportion were referred formally by clinicians as part of
the diagnostic process. In these cases, an echocardiogram was
requested in order to exclude a significant pericardial effusion, to
look for vegetations on the heart valves or to assess ventricular
function.
As a result, 240 HIV positive patients - 164 injection drug users,
48 homosexuals, 18 heterosexuals and 10 haemophiliacs -
underwent echocardiography on one or more occasions over a 27
month period. It was planned to repeat echocardiography
approximately every six to eight months or sooner if clinically
indicated, particularly in those patients whose index ultrasound was
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abnormal. More frequent studies would have been impossible in a
population consisting mainly of injection drug users who were often
reluctant to enter the ultrasound suite and remain still for the
duration of the examination. Furthermore, there were potential
ethical objections to performing frequent studies on patients whom
some clinicians felt were being over investigated already. In
practice, however, the ultimate limiting factor, particularly amongst
injection drug users, was the mood of the patient on the day of the
clinic, subject as it was to their state of health and various social
factors.
The City Hospital cohort provided 209 of the 240 individuals
studied. By 1993, the last complete year for which data is
available, 403 HIV patients were attending the clinic of whom 101
had AIDS. Demographic information on this HIV cohort which
comprised a broad range of age groups and CD4 counts is given in
Table 3.1.
3.3.2 Echocardiography
Hewlett Packard Sonos 100 and 1000 machines with 2.5 and 3.5
MHz transducers were used to measure left ventricular end-
diastolic and end-systolic diameters. On-screen calipers were used
to make these measurements from M-mode tracings derived from a
short axis view at the level of the mitral valve papillary muscles
with the patients in the left lateral position. Fractional shortening
was calculated from the difference between the two values divided
































































for M-mode analysis and assessment was made exclusively on the
two dimensional echocardiograms. Four of these individuals were
classified as suffering from heart muscle disease (two dilated
cardiomyopathy, two isolated right ventricular dilation) and 28
were said to be normal.
All the ultrasound data were stored on videotape for subsequent
detailed analysis by two independent observers and the operator.
3.3.2.1 Definitions:
a) dilated cardiomyopathy: a fractional shortening of less than
28% and global left ventricular hypokinesia reported by all three
observers.
b) borderline left ventricular dysfunction: a fractional shortening
of more than 28% together with a left ventricular end-diastolic
dimension of more than 58mm, or dilated cardiomyopathy reported
by only one or two of the three observers.
c) isolated right ventricular dilation: right ventricle equal in size
or larger than the left ventricle on two dimensional views and
normal left ventricular size and function.
3.3.3 CD4 count and clinical parameters
Blood was usually drawn at the time of the echocardiogram as part
of an ongoing, comprehensive follow up programme. Many of the
patients were attending the HIV clinic at frequent intervals making
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it possible to obtain blood in 74.6% of cases (179 out of 240)
within one month of the ultrasound study. CD4 counts for the
remainder were taken within three months of the echocardiogram
except for four patients, all of whom were injection drug users with
no evidence of heart muscle disease.
CD4 counts were performed in the Royal Infirmary HIV
Immunology Laboratory using a Becton Dickinson FACScan™
flowcytometer. Where indicated, a brief cardiovascular
examination was carried out and the results documented.
Casenotes were made available for retrospective assessment of
symptoms, physical findings, details of therapy and the results of
other relevant investigations.
3.3.4 Statistics
Statistical analysis was performed using Minitab (version 7.2,
Minitab Inc; USA) on an IBM compatible personal computer.
Two-sample t tests and Mann-Whitney U tests were used for
comparing parametric and non-parametric variables respectively.
Chi Square tests were used when appropriate. A p value of less
than 0.05 was taken as indicating a statistically significant
difference.
3.4 RESULTS
The demographic and haematological characteristics of the cohort






























































































in Table 3.3. The CDC classification used during the study was
based upon the 1986 criteria (Morbidity and Mortality Weekly
Report 1986). The breakdown of CD4 counts for each of the
various risk groups is shown in Figure 3.1. Almost 77% of the
cohort had CD4 counts less than 200 cells//d. Many of the
remainder had counts only slightly above this figure and the rest
were included largely because they had been referred formally for
ultrasound assessment. The median CD4 count of the homosexuals
was significantly less than that of both the injection drug users and
heterosexuals indicating more advanced disease. Further evidence
that the homosexuals had more advanced HIV disease comes from
the finding that all but four of the 45 patients within this subgroup
who had a CDC classification were in group IV with or without
AIDS. This reflects the fact that homosexuals in the Lothians were
the first group to acquire HIV infection in the early 1980's,
followed by injection drug users a couple of years later (Robertson
et al 1986).
3.4.1 Echocardiographic abnormalities of ventricular size and
function
Thirty-four patients (10 homosexuals, 21 injection drug users, two
haemophiliacs and one heterosexual) had evidence of heart muscle
disease on their first ultrasound study giving a prevalence of
14.2%. The remaining 206 patients had structurally normal hearts.
Table 3.4 lists the breakdown of heart muscle disease groups
according to risk factor and CD4 count. Their CDC classification


























































































































































































Twenty-six heart muscle disease patients had symptoms and/or
signs potentially attributable to cardiac dysfunction and eight were
completely well from a cardiovascular viewpoint. Despite this,
only three of these patients were identified as possibly suffering
from a cardiac disorder before their echocardiogram. Table 3.6
lists the principal clinical diagnoses of the patients with heart
muscle disease together with any symptoms and signs which may
have been attributable to cardiac dysfunction.
i) Dilated cardiomyopathy: This was found in 13 patients (eight
homosexuals, three injection drug users and two haemophiliacs) all
of whom were in CDC group IV, nine with AIDS. Their median
CD4 count was 10 cells//xl (range 0 - 145 cells/^1), significantly
less than that of all the other groups including those patients with
structurally normal hearts. The median fractional shortening was
21% (range 14 - 27%) based upon the 11 out of 13 patients who
had analysable M-mode images. There was a significant over-
representation of homosexuals (16.7% affected vs 1.8% of injection
drug users affected, p < 0.001), probably because the homosexual
patients had more advanced HIV disease.
Eight of these patients had symptoms and/or signs of heart failure
including fatigue, breathlessness, tachycardia, ankle oedema, gallop
rhythm and pulmonary crackles. The remaining five individuals














































































































































One AIDS patient presented with breathlessness, abdominal
distension and ankle swelling following a blood transfusion.
Clinical examination revealed signs of biventricular failure and he
responded well to intravenous followed by oral diuretics and
subsequent therapy with captopril. His ultrasound images are
shown in Figure 3.2.
Another individual also suffering from AIDS was referred for
echocardiography because of profound fatigue. Although he had no
overt manifestations of left ventricular failure at the time of his
index echocardiogram, these developed rapidly within the next few
weeks and he died subsequently of cardiogenic shock.
ii) Borderline left ventricular dysfunction: Twelve patients were
identified in this group. Ten were injection drug users and two
were homosexual. These patients had less advanced HIV disease
compared to the group with dilated cardiomyopathy. Only six
patients (50%) had AIDS, three (25%) had group IV disease
without AIDS and the remainder (25%) were in CDC group III.
The observation that their median CD4 count of 100 cells//A (range
4 - 783 cells//xl) was significantly greater than that of patients with
dilated cardiomyopathy (but no different to any other group) is
consistent with their having less advanced HIV disease. Their
median fractional shortening was 35% (range 24 - 41%). Ten
patients had symptoms and four had signs consistent with impaired
left ventricular function. One patient with marked dilation of a left
ventricle with normal systolic function (Figure 3.3) had moderate
FIGURE 3.2 M-mode echocardiogram (short axis view) of
patient with dilated cardiomyopathy.
RV - right ventricle, IVS - interventricular septum, LV - left
ventricle.
FIGURE 3.3 M-mode echocardiogram (short axis view) of a
patient with borderline left ventricular dysfunction.
The left ventricle is dilated considerably.
IVS - interventricular septum, LV - left ventricle.
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mitral regurgitation atop a background of previous staphylococcal
endocarditis.
iv) Isolated right ventricular dilation: Nine patients were found
with this condition. Eight were injection drug users and one was
heterosexual lending support to the theory (see below and also
Section 1.12) that pressure loading, in this case through particulate
matter introduced into the lungs causing pulmonary hypertension,
may have been an aetiological factor. Their median CD4 count
was 56 cells//d (range 4 - 266 cells//d), significantly greater than
that of the patients with dilated cardiomyopathy but no different to
that of any other group. Although all nine patients had group IV
disease, only three (33%) were suffering from AIDS. Their
median left ventricular fractional shortening was normal at 36%
(range 28 - 51%). Eight patients complained of breathlessness or
fatigue but none had overt signs of right ventricular dysfunction.
One patient had a large pericardial effusion and clinical and
Doppler evidence of pulmonary hypertension (Figure 3.4). A
subsequent perfusion lung scan indicated a high probability of
multiple pulmonary emboli and warfarin therapy was started.
3.4.2 Serial echocardiograms
Of the 240 patients recruited, 115 underwent further
echocardiography including 23 with heart muscle disease (Figure
3.5). Of the 125 patients who did not have additional ultrasound
examinations, 39 died prior to their repeat study, 41 had their first
echocardiogram within eight months of the end of the study period
FIGURE 3.4 Echocardiograms (parasternal long axis and
short axis views) of a patient with isolated right ventricular
dilation.
The right ventricle is enlarged, pushing the interventricular
septum towards the left ventricle.






















































and 45 failed to return for follow up, attended clinics outside
Edinburgh or refused to participate further.
3.4.2.1 Dilated cardiomyopathy group:
Seven out of the 13 patients with dilated cardiomyopathy underwent
repeat echocardiography (2.3 ±_ 0.5 echocardiograms per patient,
median interval 119 days, range 49 - 476 days). Of those that were
not restudied, three died within a few months of the index
echocardiogram, one went to prison and subsequently died and two
were lost to follow up. In every case there was evidence of
persistent global impairment of left ventricular function.
3.4.2.2 Borderline left ventricular dysfunction group:
Eight patients out of this group of 12 underwent repeat
echocardiography (2.9 +_ 0.8 echocardiograms per patient, median
interval 189 days, range 126 - 532 days). Of the remainder, two
patients died within six months of their first echocardiogram, one
individual underwent ultrasound examination less than six months
before the end of the study and one was lost to follow up. Two
patients reverted to normal and the remainder were unchanged.
One of the patients whose cardiac abnormalities resolved was
shown subsequently to have been suffering from Pneumocystis
carinii pneumonia at the time of his initial echocardiogram.
3.4.2.3 Isolated right ventricular dilation group:
Eight of the nine patients underwent repeat echocardiography (3.1
±_ 0.8 echocardiograms per patient, median interval 182 days,
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range 63 - 406 days). The remaining individual died less than six
weeks after his index ultrasound. The right ventricle in five of
these patients subsequently became normal. Retrospective analysis
showed that three of these individuals had a chest infection at the
time of their initial assessment. Of the remaining three patients
with persistent right ventricular dilation, one had pulmonary
hypertension and another tricuspid valvular incompetence due to
previous endocarditis. There was just one individual suffering
from disease of the right ventricle who was not an injection drug
user. He had no cardiac symptoms and was hospitalised at the time
of his echocardiogram because of anorexia, weight loss and
dysphagia. This was caused by disseminated abdominal lymphoma
from which he died six weeks later.
3.4.2.4 Event rate:
Ninety-two patients with normal hearts underwent repeat
echocardiography (2.7 ±_ 0.9 echocardiograms per patient, median
interval 182 days, range 14 - 717 days). Two patients developed
dilated cardiomyopathy. Both had AIDS and there was no evidence
of recent acute secondary infection to account for the marked
decline in left ventricular function. One patient first underwent
echocardiography during the course of an admission with
Pneumocystis carinii pneumonia. At that time his ultrasound
examination was entirely normal and there were no signs of heart
failure on his chest X-ray (Figure 3.6). However, his ECG showed
profound first degree heart block (Figure 3.7) which, in retrospect,
may have reflected an underlying myocarditis. He presented again
J
FIGURE 3.6 Initial chest X-ray on E L who subsequently
developed dilated cardiomyopathy.
The cardiothoracic ratio is 0.3 (normal < 0.5) and the lung
fields are clear.
FIGURE 3.7 Initial ECG on E L who subsequently developed
dilated cardiomyopathy.
This shows marked first degree heart block.
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eight months later with marked dyspnoea, a productive cough,
fever and constitutional upset. Although he had clinical evidence of
left ventricular failure, he was treated for a presumptive recurrence
of Pneumocystis carinii pneumonia. His chest X-ray now showed a
marked increase in heart size together with pulmonary oedema
(Figure 3.8). Echocardiography confirmed that his left ventricular
function had deteriorated substantially. Although the first degree
heart block had disappeared, he had acquired non-specific T wave
changes on his ECG (Figure 3.9). Endomyocardial biopsies (Figure
3.10) were effectively normal with no histological evidence of
ongoing inflammation or infiltration with Toxoplasma gondii or
cytomegalovirus (see Chapter 4). His condition improved with
diuretics and ACE inhibitor therapy and he survived for another six
months before dying from cardiac failure. Dilated cardiomyopathy
was confirmed at autopsy. The other patient pursued a similar
course with profound deterioration in left ventricular function over
a six month period and death just nine months after the diagnosis of
dilated cardiomyopathy had been made.
A further two individuals developed borderline left ventricular
dysfunction, again with no apparent acute precipitating cause. In
contrast to the patients with dilated cardiomyopathy, both were well
with no signs of left ventricular failure. The two patients had
further ultrasound examinations which showed persistent borderline
left ventricular dysfunction. One patient died from an AIDS related
illness just over two years after the first abnormal echocardiogram
and the other survived for 21 months before dying at home.
FIGURE 3.8 Later chest X-ray from E L (cf. Figure 3.6)
taken after dilated cardiomyopathy diagnosed.
The cardiothoracic ratio has increased to 0.6 and there is some
patchy opacification in the lung fields.
FIGURE 3.9 Later ECG from E L (cf. Figure 3.7) performed
after dilated cardiomyopathy diagnosed.
The first degree heart block has resolved and there are now
non-specific inferolateral T wave abnormalities.
FIGURE 3.10 Histology of an endomyocardial biopsy taken
from E L after dilated cardiomyopathy diagnosed.
The appearances are entirely normal.
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Neither patient underwent autopsy.
Thus, over a total of 94.6 patient-years, four individuals developed
cardiac dysfunction making the combined event rate for any form
of heart muscle disease 4.23% per patient-year.
3.4.2.5 Additional observations:
Pericardial effusions were rare, being found in just four patients,
and never clinically significant. One of these patients had isolated
right ventricular dilation and multiple pulmonary emboli, two had
dilated cardiomyopathy and the fourth had normal ventricles.
Just one patient was identified with active infective endocarditis
affecting the tricuspid valve. Another had persistent mitral
regurgitation from a previous episode of staphylococcal
endocarditis.
3.5 DISCUSSION
This study has established that HIV heart muscle disease is
common and affects all the major risk groups for HIV infection in
the United Kingdom. The combined prevalence of all forms of
HIV heart muscle disease was 14.2% and dilated cardiomyopathy
in particular 5.4%. The latter lies within the 3% - 41% range
quoted by Herskowitz et al (1993) based upon an overview of six
major echocardiographic studies and close to the 14.5% found in
their own series.
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Dilated cardiomyopathy appears to be a late stage phenomenon as
evidenced firstly by the significantly lower CD4 count in patients
with this condition and secondly by the strong association with
CDC group IV disease, particularly AIDS. This accords with other
echocardiographic and post mortem studies (see Section 1.11). In
contrast, borderline left ventricular dysfunction and isolated right
ventricular dilation are found at an earlier stage of HIV infection.
Disease of the right ventricle is demonstrated almost invariably in
injection drug users only.
Although eight out of thirteen patients (61.5%) with dilated
cardiomyopathy on their index echocardiogram had symptoms or
signs consistent with impaired left ventricular function, just three
(23.1%) were considered to have a putative cardiac disorder prior
to their echocardiogram. Similar findings have been reported in an
American series evaluating heart muscle disease in a small group of
HIV positive children and reflect the tendency to ascribe symptoms
and signs of heart failure to non-cardiac causes (Lipshultz et al
1989). The results of this study reinforce the principle that patients
with symptoms and signs compatible with cardiac disease merit
formal assessment using echocardiography which is non-invasive,
convenient and safe.
The combined event rate for dilated cardiomyopathy and borderline
left ventricular dysfunction in this series was just 4.23% per
patient-year, somewhat less than the 18% per patient-year quoted
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by Herskowitz et al (1993a). There are many potential explanations
for this finding. Firstly, almost 22% of the American cohort abused
alcohol, a substance which is known to cause heart muscle disease
(Fink et al 1979). Secondly, four out of the 69 patients (6%) in that
series had hypertension. Thirdly, 38% of the American patients
were aged over 40 compared with just 10% in the Edinburgh
cohort. Another factor which may be significant is that patients in
the Edinburgh study were subject to regular review allowing
prompt treatment of associated illness and frequent respite
admissions where rest and nutritional replenishment could be
offered. In addition, many of the drug users in this cohort were
being prescribed methadone and as a result, injecting and possibly
sharing needles less often (Peters et al 1994). This would have had
the effect of reducing the risks not only of additional sepsis and
possibly the progression of HIV disease itself, but also the
deleterious financial and health consequences which usually
accompany injection drug use (Phillips et al 1994). Finally, it is
now recognised that the time from acquisition of the virus to the
development of AIDS is getting progressively longer (Rutherford
1994). A recent UK study showed that the median survival time
for patients with AIDS doubled between 1984 and 1987 (Peters et
al 1991). The rate of progression of HIV disease in the Edinburgh
cohort may therefore not have been as rapid as that in the American
study making it less likely for patients to develop end-organ
damage including cardiac dysfunction.
Dilated cardiomyopathy in this series was invariably irreversible in
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contrast to the 17% of patients with borderline left ventricular
dysfunction whose cardiac abnormalities resolved. This confirms
the findings of Blanchard et al (1991) who showed that transient
impairment of left ventricular function could occur, and that the
presence of left ventricular dysfunction on a single echocardiogram
did not necessarily imply a poor prognosis. This group of patients
may have been suffering from a transient myocarditis which could
cause a reversible reduction in left ventricular function.
There are several potential causes of isolated right ventricular
dilation. It may arise as part of a generalised myopathic process,
from pulmonary hypertension due to pulmonary emboli or recurrent
chest infections (Acierno 1989, Himelman et al 1989b, Herskowitz
and Baughman 1994), or from volume overload secondary to
tricuspid incompetence mediated by endocarditic valve damage. In
this series, five out of eight (62.5%) patients with isolated right
ventricular dysfunction returned to normal. Three of these patients
had a chest infection at the time of their initial ultrasound
assessment. Moreover, of the three patients with persistent isolated
right ventricular dilation, one had clinical evidence of pulmonary
hypertension and another had a history of prior infective
endocarditis affecting the tricuspid valve with Doppler evidence of
significant tricuspid incompetence. These findings therefore
confirm the hypothesis that a significant proportion of cases with
isolated right ventricular dilation are related to acute respiratory
tract infection or pressure/volume overload of the right ventricle
rather than a progressive myopathic process.
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3.6 CONCLUSIONS
HIV heart muscle disease is common, takes a variety of forms and
affects all major risk groups. Dilated cardiomyopathy occurs late
in the course of HIV infection and is often undiagnosed or
associated with symptoms and signs which may be attributed
mistakenly to other disease processes. It appears to be irreversible.
In contrast, borderline left ventricular dysfunction may be transient.
Sequential ultrasound assessments are therefore necessary to
confirm the presence of irreversible cardiac damage. Isolated right
ventricular dilation may also be evanescent in the context of acute
respiratory infection. Persistent cases are often related to pressure
or volume overload of the right ventricle rather than true heart
muscle disease.
Improved treatment of opportunistic infections and HIV disease
itself is likely to result in more patients surviving to develop
malignancies and end-organ failure (Coplan and Bruno 1989, Peters
et al 1991, Herskowitz and Baughman 1994). Heart failure due to
HIV heart muscle disease therefore has the potential of becoming a
significant cause of morbidity and mortality in this group. Prompt
recognition and treatment is important since palliative therapy with
diuretics and vasodilators can be very worthwhile.
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CHAPTER 4
THE ROLE OF OPPORTUNISTIC INFECTION WITH
TOXOPLASMA GONDII AND CYTOMEGALOVIRUS AND
TREATMENT WITH ZIDOVUDINE IN THE
PATHOGENESIS OF HIV HEART MUSCLE DISEASE
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4.1 SUMMARY
Infection with Toxoplasma gondii and cytomegalovirus can cause
myocarditis, a possible precursor of HIV heart muscle disease.
There is also a putative association between cardiac dysfunction and
treatment with zidovudine.
A retrospective analysis of a subgroup of 173 patients participating
in a prospective echocardiographic study was performed in order to
investigate the relationships between these factors and HIV heart
muscle disease.
Serology demonstrated that there was no excess of patients with
acute, past or recurrent infection with Toxoplasma gondii and
cytomegalovirus in the heart muscle disease group. This applied
even when patients with isolated right ventricular dilation - a
disease which may not represent a true myopathic process - were
excluded.
Analysis of the therapeutic database and case records showed that
similar proportions of patients in each of the heart muscle disease
categories and in the group with normal hearts had received
treatment with zidovudine. Although patients with isolated right
ventricular dilation and borderline left ventricular dysfunction had
received a greater total dose of zidovudine compared with the other
groups, this probably reflects prescribing practices that were
influenced by symptomatology. There were patients in all the heart
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muscle disease groups who had never received this drug.
Neither secondary infection with Toxoplasma gondii and
cytomegalovirus nor treatment with zidovudine appears to be linked
directly with the development of HIV heart muscle disease.
However, their possible role as cofactors cannot be excluded.
4.2 INTRODUCTION
Among the many putative pathogenetic mechanisms for HIV heart
muscle disease are secondary infection with the common
opportunistic agents Toxoplasma gondii and cytomegalovirus and
treatment with zidovudine (Acierno 1989, Herskowitz and
Baughman 1994).
Patients with HIV infection are prone to opportunistic infection
with (inter alia) Toxoplasma gondii and cytomegalovirus, both of
which have been shown to cause myocarditis (Roldan et al 1987,
Lafont et al 1988, Vynn Adair et al 1989, Hofman et al 1991). It is
thought that myocarditis may be the precursor of heart muscle
disease (see Section 1.11.4). Some patients could therefore
develop HIV heart muscle disease as a result of preceding
myocarditis caused by infection with these potentially cardiotropic
organisms.
Zidovudine is known to cause a dose dependent, reversible skeletal
myopathy with characteristic histological changes (Fischl 1989,
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Berger et al 1991). There are also anecdotal reports of an
improvement in cardiac function following withdrawal of
zidovudine (Herskowitz et al 1992). To date, however, there are
no large scale studies evaluating the potential aetiological role of
this drug in the development of HIV heart muscle disease.
To this end, a retrospective analysis was performed on the first 173
patients recruited as part of the prospective study described in
Chapter 3. Serology of stored blood samples was used to assess
whether HIV heart muscle disease patients showed any excess of
secondary infection with Toxoplasma gondii or cytomegalovirus.
The original intention was to evaluate this preliminary data and
then institute a formal, prospective study if the results were
positive. An assessment of therapy with zidovudine in this group
was also undertaken in order to determine whether treatment per se
or the cumulative dose rendered patients more vulnerable to any
form of HIV heart muscle disease.
4.3 MATERIALS AND METHODS
4.3.1 Epidemiology
Details of the full cohort and the methodology of the ultrasound
examinations have been described in Chapter 3. The prevalence of
HIV heart muscle disease in the subgroup of 173 patients who took
part in this phase of the study is shown in Table 4.1. CD4 counts



























































4.3.2 Infection with Toxoplasma gondii and cytomegalovirus
Blood was drawn routinely as part of the clinical assessment and
samples were sent to the City Hospital virology laboratory at the
discretion of the attending physician. After 173 patients had been
recruited, retrospective serological analysis of stored samples taken
at or within one month of the ultrasound examination was
undertaken. A toxoplasma dye test was performed if the
preliminary Toxoplasma gondii screen was positive. When this was
greater than 250 IU/ml, IgM was measured to establish if the
infection was recent. A cytomegalovirus titre of between 1 in 4
and 1 in 32 inclusive was interpreted as evidence of past infection.
In patients with titres of more than 1 in 32, IgM was measured to
determine whether the infection was primary or recurrent.
4.3.3 Treatment with zidovudine
Details of zidovudine treatment were obtained from the City
Hospital database and also by careful casenote analysis. The total
exposure to zidovudine in each patient was calculated by
multiplying the daily dose by the number of days for which that
dose had been prescribed. In 16 patients, 15 with normal cardiac
function and one with dilated cardiomyopathy, the total dose could
not be determined as documentation was incomplete.
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4.4 RESULTS
4.4.1 Secondary infection with Toxoplasma gondii and
cytomegalovirus
Of the 29 patients with cardiac abnormalities, 25 had never been
infected with Toxoplasma gondii, two had evidence of past
infection and the status of two were unknown. Seven of these 29
patients had never been infected with cytomegalovirus, three had
experienced recurrent infection around the time of their
echocardiogram and 16 had suffered past infection. The
cytomegalovirus status of three patients was unknown. As a whole,
the patients with heart muscle disease had no significant differences
in terms of infection with Toxoplasma gondii or cytomegalovirus
compared with those with normal hearts (Figure 4.1).
When the seven patients with isolated right ventricular dilation
(who may not have been suffering from true heart muscle disease -
see Section 1.12 and Chapter 3) were excluded, the findings were
not altered significantly. Of the 22 patients with heart muscle
disease, 18 had never been infected with Toxoplasma gondii, two
had evidence of past infection and the status of the remaining two
was unknown. Similarly, four patients had never been exposed to
cytomegalovirus, 12 had past infection and three were suffering
from recurrent disease. The status of the three remaining patients
was unknown.




























cardiomyopathy. It was found that nine had never been exposed to
Toxoplasma gondii and two had been infected in the past.
Similarly, three patients had never been infected with
cytomegalovirus and eight had evidence of past infection. Again, it
was apparent that there was no excess secondary infection with
these organisms in this group of patients.
4.4.2 Treatment with zidovudine
Details of zidovudine therapy in each of the heart muscle disease
groups are shown in Figure 4.2.
4.4.2.1 Normal group:
Out of 144 patients, 109 had received treatment with zidovudine
(76%). The total dose in 15 patients was unknown.
4.4.2.2 Dilated cardiomyopathy:
All but one of these 13 patients (92%) had received zidovudine. Of
those that had, the dose in one patient was unknown. Neither the
proportion of patients treated nor their median total dose was
significantly different from those patients without heart muscle
disease.
4.4.2.3 Borderline left ventricular dysfunction:
Seven out of nine patients in this group (78%) had received
zidovudine, a proportion not dissimilar to any other category.
However, their median total dose (396 grammes) was significantly












































































4.4.2.4 Isolated right ventricular dilation:
Again, although the proportion of patients treated with zidovudine
(6/7 - 86%) was similar to all other groups, the median total dose
(589.5 grammes) was significantly greater than that received by
patients with dilated cardiomyopathy (p < 0.05) and also those
with structurally normal hearts (p < 0.005).
4.5 DISCUSSION
4.5.1 Opportunistic infection
The putative role of Toxoplasma gondii and cytomegalovirus in the
pathogenesis of myocarditis and the relationship between this
condition and HIV heart muscle disease have been covered
extensively in Sections 1.10 and 1.11.4. There is no direct
evidence linking either of these organisms to HIV heart muscle
disease. However, circumstantial evidence exists to support such
an association. Wu et al (1992) obtained endomyocardial biopsies
from 12 HIV infected patients with dilated cardiomyopathy and
subjected them to in situ hybridisation. They showed that six
patients had the cytomegalovirus IE gene within their myocytes.
Neither cytomegalovirus DE transcripts nor classic inclusion bodies
were found. This would be compatible with latent cytomegalovirus
infection without active viral replication. An additional eight HIV
patients without heart muscle disease were studied. They had
neither positive in situ hybridisation signals nor histological
evidence of myocardial infection with cytomegalovirus. Similar
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results were obtained by Herskowitz et al (1994) in 37 HIV
infected patients with dilated cardiomyopathy. Unfortunately, the
demonstration of cytomegalovirus within the myocardium of
patients with heart muscle disease does not conclusively establish a
cause and effect relationship, only an association. One or both
organisms may act as cofactors in the development of HIV heart
muscle disease.
The importance of establishing whether these infectious agents play
a part in the development of HIV heart muscle disease is not only
of academic interest but also potentially of therapeutic value.
Cytomegalovirus infection may respond to ganciclovir and there is
at least one report of successful antibiotic treatment of heart failure
associated with Toxoplasma gondii (Grange et al 1990).
This study has demonstrated that secondary infection with
Toxoplasma gondii and cytomegalovirus, while common in the HIV
community, does not predispose towards heart muscle disease. It is
clear that the exposure to these pathogens in patients with and
without heart muscle disease was remarkably similar. It can be
argued that as patients with isolated right ventricular dysfunction
may have been suffering from the secondary effects of right-sided
pressure or volume overload rather than true heart muscle disease
(see Section 1.12), they should be excluded from any assessment of
the pathogenetic role of cardiotropic infection. Even when this was
done, there were no statistically significant differences between
heart muscle disease patients and those with normal cardiac
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function in terms of their exposure to either organism. This
remained true when only those patients with dilated
cardiomyopathy were assessed. The finding of crucial importance
however, is that there were patients in every heart muscle disease
group who had never been infected with either organism.
While a direct pathogenetic relationship thus appears unlikely, it is
possible that either or both organisms could act as cofactors in the
development of HIV heart muscle disease. This would accord with
the work of Wu et al (1992) and Herskowitz et al (1994) who found
evidence of an excess of latent cytomegalovirus infection within the
hearts of HIV patients with dilated cardiomyopathy.
4.5.2 Zidovudine treatment
The role of zidovudine in the development of HIV heart muscle
disease is also a matter of speculation. Zidovudine causes a
dose-dependent, reversible skeletal myopathy with characteristic
histological abnormalities which improve when the drug is
withdrawn (Fischl 1989, Dalakas et al 1990, Berger et al 1991)
(see Section 1.11.6 and Figures 1.3 and 1.4). Cardiac muscle in
rats can also be affected in a similar fashion (Lamperth and Dalakas
1991).
Herskowitz et al (1992) described a group of 26 HIV patients with
congestive cardiac failure, 13 of whom were receiving
antiretroviral therapy. Six of these patients had temporal changes
in left ventricular function related to treatment with zidovudine,
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three individuals subsequently reverting to normal after the drug
had been discontinued. Two of these three patients had an active
myocarditis with predominantly CD8 lymphocytic infiltrates.
Other features of zidovudine toxicity including bone marrow
suppression and myositis were also noted.
It is difficult to know how much the anaemia which is often
associated with zidovudine therapy (Richman et al 1987)
contributes to cardiac failure and therefore whether any
improvement in left ventricular function is attributable to an
increase in the number of circulating red blood cells rather than to a
direct effect of drug withdrawal. This issue was neither mentioned
nor addressed in the American study (Herskowitz et al 1992).
Their recommendations were that patients who developed heart
failure while receiving treatment with zidovudine should have the
drug withdrawn empirically for one month and that cardiac function
should be monitored closely if therapy was reintroduced
subsequently.
In the Edinburgh study, there was no excess prevalence of patients
treated with zidovudine in the heart muscle disease group as a
whole. Although the majority of patients in each of the heart
muscle disease groups had indeed received the drug, the proportion
of individuals treated was not significantly different from those with
structurally normal hearts. Moreover, there were patients in each
heart muscle disease group who had never received zidovudine.
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It is not clear why patients with isolated right ventricular dilation
and borderline left ventricular dysfunction had received a
significantly greater total dose of zidovudine compared with those
with dilated cardiomyopathy and normal hearts. One possible
explanation is that patients who have been hospitalised with
respiratory infections, and who are therefore more at risk of
developing isolated right ventricular dilation (see Chapter 3 and
Section 1.12), are also more likely to be commenced on zidovudine
than those remaining well in the community. Furthermore, the
overwhelming majority (18/21) of patients with borderline left
ventricular dysfunction and isolated right ventricular dilation had
symptoms and signs (see Section 3.4.1 and Table 3.6) which may
have brought them more frequently to the attention of the medical
staff who may have been influenced sufficiently to either initiate
treatment with zidovudine or increase the dose. Conversely,
patients with dilated cardiomyopathy received a significantly
smaller total dose of zidovudine compared with those with isolated
right ventricular dilation. As patients with dilated cardiomyopathy
had more advanced HIV disease, they would have been more likely
to have developed side effects from prolonged treatment with
zidovudine which would have been reduced or discontinued as a
result. At the time of the study, the antiretroviral policy was to
offer zidovudine to all patients with CD4 counts of less than 350
cells//d, particularly if they had clinical evidence of
immunosuppression. If zidovudine toxicity developed, such as
anaemia requiring blood transfusions or intolerable gastrointestinal
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side effects, the dose was either reduced or the drug withdrawn. A
few individuals were switched to ddl (didanosine) which was at that
time undergoing preliminary evaluation on a named patient basis
(Brettle - personal communication).
4.6 LIMITATIONS OF THE STUDY
This study was conducted in a retrospective fashion and it was
therefore not possible to determine the Toxoplasma gondii and
cytomegalovirus status in all the patients. Another difficulty is that
the accuracy of serological analysis is questionable in a group of
individuals with profound disruption of the immune system.
However, many HIV patients including some with heart muscle
disease underwent endomyocardial biopsy or were studied at
autopsy. Histology of their cardiac tissue invariably showed no
evidence of active infection with either of these pathogens.
The validity of the zidovudine data depends in part upon patients
taking their drugs as prescribed. While it was not possible to
assess this accurately, the majority (100/118 - 84.7%) of patients
who were prescribed zidovudine had elevations of mean
corpuscular volume, a feature which is commonly associated with
such treatment (Richman et al 1987). Moreover, recognised side
effects occurred in many patients. There is no reason to suspect
that compliance with treatment was any different either in the




Although this study has its limitations, it demonstrates that HIV
heart muscle disease is not related primarily either to secondary
infection with Toxoplasma gondii and cytomegalovirus or to
treatment with zidovudine. It is possible, however, that one or
both of these agents may help to promote the development of
cardiac dysfunction in patients who have been rendered vulnerable
to heart damage by other factors such as nutritional deficiencies
(Chapter 6) or direct infiltration of the myocardium by HIV
(Chapter 5). Patients who develop heart failure while being treated
with zidovudine should have the drug discontinued empirically for
one month with further assessments of cardiac function thereafter.
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CHAPTER 5
MYOCARDIAL INFILTRATION BY HIV - A POTENTIAL
CAUSE OF HIV HEART MUSCLE DISEASE?
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5.1 SUMMARY
The precise cause of HIV heart muscle disease is unknown but
infiltration of the myocardium by the virus has been implicated.
The evidence for such infiltration is contradictory and a consistent
association with heart muscle disease has never been shown.
This study was performed in order to determine firstly whether the
virus was present in the myocardium and secondly if it was
replicating.
Twelve HIV patients, five of whom had echocardiographic
evidence of left or right ventricular dysfunction, were assessed.
Cardiac tissue obtained at autopsy was subjected to the polymerase
chain reaction (PCR) in order to detect the presence of the virus.
Peripheral blood lymphocytes harvested within six months of death
also underwent PCR in order to assess the possibility that positive
myocardial signals emanated from contaminating infected
immunocytes. Immunohistochemistry using antibodies directed
against the p24 and group 120 antigens, markers of viral
replication, was performed on the cardiac samples.
Eleven of the 12 patients, including all those with ventricular
abnormalities, had HIV present within the myocardium. Patients
with the highest myocardial concentrations of the virus had heart
muscle disease. There was no evidence that HIV was replicating
within the heart.
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HIV can infiltrate the myocardium and may be present in relatively
high concentrations, particularly in patients with heart muscle
disease. Any deleterious effects of HIV upon the heart do not
appear to be mediated by viral replication.
5.2 INTRODUCTION
Up to 6.2% of patients with late stage HIV disease develop severe,
global left ventricular impairment (Herskowitz et al 1993a). Peters
et al (1991) have reported that fewer HIV patients are dying of
opportunistic infection, resulting in more deaths through
malignancy and end-organ failure including heart muscle disease.
As between 30 and 40 million people may have contracted the virus
by the year 2000 (WHO press release, WHO/30, 10 April 1994),
there exists the potential for a dramatic increase in the prevalence
of HIV induced heart failure early in the next century.
The precise cause of HIV heart muscle disease is unknown but
putative aetiological factors include direct infiltration of the
myocardium by HIV, secondary infection with opportunistic
organisms such as cytomegalovirus, treatment with potentially
cardiotoxic drugs including zidovudine, and nutritional deficiencies
particularly of antioxidants such as selenium (Acierno 1989,
Herskowitz and Baughman 1994).
HIV heart muscle disease shares similar clinical and
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echocardiographic features with idiopathic dilated cardiomyopathy,
a condition which may be related to previous infection with a
variety of enteroviruses (Tracy et al 1990). Much of the evidence
linking enteroviral infection with idiopathic dilated cardiomyopathy
is circumstantial and contradictory. Such evidence is based upon
serological techniques as well as the demonstration of viral material
in the myocardium using in situ hybridisation and PCR (Jin et al
1990, Kandolf et al 1987).
Studies of the role of direct viral infiltration of the myocardium in
the pathogenesis of HIV heart muscle disease are equally
contradictory. Some groups have demonstrated the presence of
HIV within the myocardium using co-culture techniques (Dittrich et
al 1988), in situ hybridisation (Grody et al 1990) and PCR
(Flomenbaum et al 1989, Lipshultz et al 1990, Rodriguez et al
1991). Others, however, have failed altogether to find HIV in the
heart (Beschorner et al 1990, Herskowitz et al 1990b) and no group
has yet shown a conclusive association between the presence of
virus and heart muscle disease.
Infiltration of the myocardium by HIV could cause tissue
destruction directly either by viral replication or the induction of
apoptosis, or indirectly through cell surface expression of novel
antigens (including those of the major histocompatibility complex
locus) or by an innocent bystander mechanism (see Chapter 1).
When HIV replicates within infected cells, viral proteins such as
the core antigens p24 and group 120 are produced by translation
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from the viral mRNA. These are later transported to the cell
surface where new viruses form and are subsequently released by
budding (Yarchoan and Broder 1989). Such surface proteins can
be identified using the appropriate monoclonal antibodies and they
provide an indirect means of detecting intracellular viral
replication.
This study was performed in order to try and establish whether
patients infected with HIV had the virus present within the
myocardium and if so, whether there was evidence of viral
replication. An attempt was made also to correlate myocardial HIV
concentrations with heart muscle disease.
5.3 SUBJECTS AND METHODS
5.3.1 Patients
Ten patients out of the 240 HIV positive individuals participating in
the prospective echocardiographic study died and were subjected to
autopsy. Nine of these patients were suffering from AIDS and one
had AIDS related complex. Risk factors for HIV infection were
injection drug use in five and homosexual practices in the
remainder. The CD4 count was usually estimated at the time of the
ultrasound scan and invariably within six weeks as part of a regular
outpatient assessment. The median CD4 count was 10 cells/^1
(range 0-160 cells/yrd; normal 400 - 1500 cells/jitl).
Autopsy cardiac tissue from these individuals was retained for
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study. Peripheral blood lymphocytes obtained within six months
prior to death were also available in this group.
Two HIV positive patients (both injection drug users) presenting
for the first time at post mortem without preceding
echocardiography were also studied together with two seronegative
controls, one of whom ultimately underwent cardiac
transplantation.
5.3.2 Echocardiography
This was performed within six months prior to death; in five cases,
within one month. A diagnosis of heart muscle disease was made
on the basis either of global left ventricular hypokinesia and
fractional shortening of less than 28% or left ventricular end-
diastolic diameter more than 58 mm without loss of function.
Isolated right ventricular dilation was said to be present when the
function of the left ventricle was normal but the right ventricle was
larger than the left on standard two dimensional views.
5.3.3 Detection of HIV within tissue
Two complementary techniques were employed looking firstly for
the presence of HIV within cardiac tissue and secondly for evidence
of viral replication.
5.3.3.1 PCR:
A modified double PCR method with a limit dilution approach was
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used to determine cellular concentrations of HIV provirus
(Simmonds et al 1990a). In order to try and determine whether a
positive myocardial PCR signal emanated from contaminating
infected immunocytes, peripheral blood lymphocytes from the same
patient were studied simultaneously. As there was no histological
evidence of an inflammatory infiltrate in any of these patients, the
assumption was made that a maximum of 10% of the nucleic acids
from the myocardial tissue was attributable to circulating
immunocytes. Thus, if the myocardial HIV concentration was
more than 10% that of the peripheral blood lymphocytes, then this
was taken to indicate that HIV was present within the tissue itself
as opposed to within contaminating immunocytes. Ventricular
muscle was obtained at post mortem and stored at -80°C until
required. A 150 mg block of tissue was macerated and then added
to 0.25% collagenase B in RPMI solution to give a final volume of
two mis. This was then incubated at 37°C for two hours after
which the nucleic acids were extracted using phenol and carbon
tetrachloride. The resulting mixture was precipitated overnight
using ethanol in a -20°C freezer and then desiccated at 65°C. A
similar method was used to extract nucleic acids from the
lymphocytes which had been separated from whole blood and
subsequently deep frozen until required. The nucleic acid material
then underwent PCR.
5.3.3.2 Immunohistochemistry for p24 and group 120 antigens:
Evaluation of p24 and group 120 antigen expression was performed
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separately using a standard avidin biotin method applied to 5-10
micron acetone fixed cryostat sections of myocardium. At least
three sections of heart from each patient were studied during each
immunohistochemical run. After being washed, the sections were
incubated in a 3% solution of hydrogen peroxide in methanol for 10
minutes in order to block endogenous peroxidases. Following a
further wash in water and two changes of phosphate buffered saline
(PBS), the sections were then incubated in a solution containing the
primary antibody (p24 or group 120) at room temperature for 30
minutes. For the p24 antigen assays, normal rabbit serum was
used, while in the case of the group 120 antigen, normal swine
serum containing tween was found to give the most reproducible
results. The sections were again washed twice in PBS before being
incubated for 30 minutes in 1:200 biotinylated rabbit anti-mouse or
swine anti-rabbit antibodies as appropriate. After two more
washes, the sections were incubated with diaminobenzidine (DAB)
for 10 minutes prior to haematoxylin staining. Sections of brain
obtained at post mortem from HIV infected individuals and known
to express p24 and group 120 antigens acted as positive controls for
each experiment. As lipofuscin within the myocardium was a
potential source of confusion with DAB deposition,
aminoethylcarbazole (AEC) was used as an alternative chromagen
in all the experiments.
Statistical comparisons were made using the Minitab programme




These are shown in Table 5.1. Of the 12 HIV patients studied, 10
had ante mortem echocardiographic evaluation. Of these, four had
heart muscle disease affecting the left ventricle and one had isolated
right ventricular dilation. The remaining five patients had
echocardiographically normal hearts. Heart muscle disease was
found both in injection drug users and in homosexuals.
Microscopic examination was unremarkable in all patients,
including those with heart muscle disease, with no evidence of
myocarditis (Figures 5.1 & 5.2).
5.4.1 PCR results
Eleven of the 12 patients had a positive cardiac PCR signal. All
five of the patients with echocardiographic abnormalities had a
positive signal. This included three individuals with concentrations
of HIV within the heart equal or substantially greater than that of
the peripheral blood lymphocytes suggestive of a large myocardial
viral load. The remaining two patients with heart muscle disease
had concentrations of HIV within the heart less than 10% that of
the lymphocytes indicating possible myocardial contamination by
circulating immunocytes. As a group, the five patients with heart
muscle disease had a median ratio of heart to lymphocyte HIV
concentration of 100% (mean 178.8%, standard deviation 201.9%,
range 5.5% - 458.6%) compared to a median of 9.8% (mean
























































































































FIGURE 5.1 Histology of frozen section of myocardium taken
from an HIV positive patient.
A special stain has been used to detect the presence of




FIGURE 5.2 Histology of frozen section of myocardium taken
from an HIV positive patient (H and E stain).
The appearances are normal except for contraction bands
(arrow) which represent artefact.
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structurally normal hearts. This difference was not statistically
significant using the Mann Whitney U test. Of the five patients
with echocardiographically normal hearts, just one had a significant
concentration of HIV within the myocardium while another had a
completely negative cardiac PCR signal (although HIV was
detected in his lymphocytes). The two patients who had no
ante mortem echocardiographic evaluation both had concentrations
of HIV within the myocardium greater than 10% that of the
peripheral blood lymphocytes. All patients, as expected, had a
positive PCR result from their peripheral blood lymphocytes. The
two non-HIV controls had absent PCR signals.
5.4.2 Immunohistochemistry results
Without exception, there was no evidence of p24 or group 120
antigen expression in the cardiac frozen sections implying lack of
viral replication. The brain controls did yield positive results
however, validating the assay (Figure 5.3).
5.5 DISCUSSION
The cause of HIV heart muscle disease remains obscure. Several
factors may be responsible, either singly or in combination,
including direct infiltration of the myocardium by HIV (Acierno
1989, Herskowitz and Baughman 1994). HIV heart muscle disease
has much in common with idiopathic dilated cardiomyopathy, a
condition which is thought also to have a viral aetiology (Tracy et
al 1990).
FIGURE 5.3 Staining of p24 antigen in a frozen section of
brain from an HIV positive patient is seen at the centre of the
photograph.
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Some groups have demonstrated that patients with idiopathic dilated
cardiomyopathy have serological evidence of recent or past
enteroviral infection (Tracy et al 1990) and that class I and II major
histocompatibility complex antigens are expressed in the
myocardium (Herskowitz et al 1990a) and arteriolar endothelial
cells (Beschorner et al 1990, Herskowitz et al 1994). This
phenomenon is not found in normal heart (Herskowitz et al 1990a)
and occurs only when there is local activation of the immune
system.
In situ hybridisation (Tracy et al 1990) and PCR techniques
(Keeling et al 1992) have been used to demonstrate the presence of
enteroviral genomic material in endomyocardial biopsy and post
mortem cardiac tissue of patients suffering from idiopathic dilated
cardiomyopathy.
Although the presence of enterovirus within the heart does not
indicate conclusively a cause and effect relationship, it does lend
support to the hypothesis that direct viral infiltration may
predispose to myocardial damage. However, the evidence is
contradictory. The study by Keeling et al (1992) for example,
showed that enteroviral infection was ubiquitous in the community
and that there was no significant association with heart muscle
disease. There is also no consensus regarding the mechanisms of
viral mediated damage.
96
The results of work looking for a link between infiltration of the
myocardium by HIV and heart muscle disease are equally
contradictory. Moreover, no consistent attempt has been made
either to localise HIV within the myocardium or to determine
whether there is evidence of viral replication. Such replication
would destroy the myocytes and might therefore represent one
mechanism whereby HIV induced myocardial damage is wrought.
When HIV replicates, there is cell surface expression of p24 and
group 120 antigens which can be detected using antibodies
available either commercially or through the Medical Research
Council AIDS Directed Programme.
One group showed that the virus was present within myocardial
cells using co-culture techniques, but then failed to confirm this
result using immunohistochemistry (Dittrich et al 1988).
Flomenbaum et al (1989) found that three out of four HIV patients
with normal cardiac function had PCR evidence of intramyocardial
HIV. Two separate groups (Grody et al 1990 and Lipshultz et al
1990) found HIV within post mortem cardiac tissue using in situ
hybridisation, but could not correlate this with either clinical or
histological abnormalities. Herskowitz et al (1994) evaluated
endomyocardial biopsies from 33 HIV patients with moderate to
severe left ventricular dysfunction on echocardiography. Five
patients had in situ hybridisation evidence of HIV within myocytes
and three of this group had positive signals emanating from
interstitial mononuclear cells also. Rodriguez et al (1991)
demonstrated using PCR that two out of five patients with heart
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muscle disease had HIV within the myocardium. However, 60%
of their HIV infected controls with structurally normal hearts also
had positive PCR signals.
These apparently positive results have to be interpreted with
caution given that both Herskowitz et al (1990b) and Beschorner et
al (1990) failed to demonstrate HIV in endomyocardial biopsy and
post mortem samples of cardiac tissue from patients with heart
muscle disease using in situ hybridisation.
On the other hand, these negative results may themselves be
misleading. It is possible that virus is actually present within the
heart and yet is overlooked because very few cells have been
infiltrated. There is supporting evidence for this theory from two
studies. In the in situ hybridisation work by Herskowitz et al
(1994) cited above, positive signals for HIV were present in only
scattered, isolated myocytes. Similarly, it is recognised that even
in patients with late stage HIV disease, just 1 in 700 CD4 target
cells are infected (Simmonds et al 1990a).
This study shows that in some cases, there are proportionately far
larger concentrations of HIV within the myocardium relative to
peripheral blood lymphocytes - the cell type regarded as being the
primary target for the virus. Although a statistically significant
relationship between the concentration of HIV within the
myocardium and the presence of heart muscle disease has not been
demonstrated, it may be of significance that the two patients whose
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cardiac tissue contained the most HIV had heart muscle disease,
while of the two patients with lesser, but still substantial
concentrations, one had isolated right ventricular dilation. It must
be borne in mind, however, that isolated right ventricular dilation
may not represent heart muscle disease, but rather a transient
phenomenon associated with respiratory infections or injection drug
use (see Section 1.12).
Two important questions are raised as a result of this work.
Firstly, in which cell type within the myocardium does HIV reside?
Secondly, how could the presence of virus within the tissue
promote the development of heart muscle disease?
Cardiac myocytes do not contain CD4 receptors (Grody et al 1990)
which means that the entry of HIV would have to be mediated by
other receptors. There is increasing evidence that galactosyl
ceramide, Fc and complement receptors are also involved in cell
penetration by HIV (Levy 1993). Recent work from the USA has
not only shown that HIV can gain entry to foetal cardiac myocytes,
but also that this process is probably mediated by the Fc receptor
(Herskowitz et al 1993b). In this context, it should be noted that
HIV can enter tissues which do not contain CD4 receptors such as
colonic cancer cells (Heyworth et al 1991), skin fibroblasts and
some nerve and liver cells (Levy 1990).
It is unclear which cells in the myocardium harbour HIV.
Possibilities include the myocytes themselves, interstitial dendritic
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cells and endothelial cells (Herskowitz et al 1993b). In situ
hybridisation should be able theoretically to address this question
but technical problems have meant that no clear answer has
emerged (Grody et al 1990). The precise location of HIV within
individual cells may indicate the manner in which it exerts its
deleterious effects. By analogy with idiopathic dilated
cardiomyopathy, mitochondrial damage may result in cell and
ultimately organ failure. In the context of HIV infection, it may be
of relevance that Flomenbaum et al (1989) described finding
lamellated bodies using electron microscopy near the mitochondria
of seropositive patients. Unfortunately, in situ hybridisation to date
has been singularly unsuccessful in consistently detecting HIV
within cardiac myocytes let alone defining its proximity to
intracellular organelles.
The mechanisms whereby intracellular HIV promotes tissue
damage therefore remain speculative. The lack of a clear
relationship between the concentration of HIV within the
myocardium and heart muscle disease suggests that viral
infiltration is not the sole aetiological factor. Moreover, the results
of this study suggest that heart muscle disease occurs in the absence
of intramyocardial viral replication. This has been postulated by
Herskowitz et al (1994) and it accords also with the results of work
performed on peripheral blood lymphocytes in HIV infected
patients. Simmonds et al (1990a) showed that the numbers of such
cells containing HIV provirus (i.e. HIV integrated into the host cell
genome) were between 1 in 700 and 1 in 80 000. However, earlier
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work by Harper et al (1986) indicated that only between 1 in
10 000 and 1 in 100 000 peripheral blood lymphocytes contained
HIV RNA sequences, the hallmark of transcriptionally active or
replicating virus. Indeed, in half of their samples, there was a
complete absence of viral transcripts. Taken together, these results
imply that even in patients with late stage HIV disease, only a small
minority of infected peripheral blood cells contain actively
replicating virus.
It is possible that HIV induces tissue damage by autoimmune
mechanisms such as the innocent bystander phenomenon whereby a
local immune reaction generates lymphokines which mediate
generalised tissue destruction (Ho et al 1987). In this way, a small
focus of inflammation can trigger widespread damage like ripples
on a pond.
There is also some evidence to support the involvement of the
immune system in HIV heart muscle disease. Herskowitz et al
(1994) showed a marked excess of class I major histocompatibility
complex antigen expression on the surface of cardiac myocytes of
HIV patients with heart muscle disease associated with a CD8
lymphocytic infiltrate. This confirmed previous work by the same
group (Herskowitz et al 1990a) and also that of Beschorner et al
(1990).
Other factors may contribute such as an excess of free radicals
liberated from leukocytes (Revillard 1991) which overwhelm local
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antioxidant defence mechanisms. Such defences may themselves
have been depleted by the nutritional deficiencies which are
common in late stage HIV infection (Kotler 1989). Alternatively,
HIV infiltration of myocytes could result in programmed cell death
(apoptosis) (Dalgleish and Colizzi 1992, Ameisen 1994).
The apparent lack of intramyocardial HIV replication and absence
of p24 and group 120 antigen expression on myocyte surfaces
imply that once HIV has entered the heart, its presence is
undetectable both by conventional immunological techniques and
presumably also by host surveillance mechanisms. This may
explain in part why not all groups have demonstrated HIV within
endomyocardial biopsy and post mortem cardiac samples.
Thus, although HIV does not appear to replicate within the
myocardium, it does seem capable nevertheless of initiating the
processes that result ultimately in irreversible cardiac failure.
5.6 LIMITATIONS OF THE STUDY
One of the drawbacks of this study was the small number of
patients investigated. Secondly, the assumption that up to 10% of
the nucleic acids within the myocardium were attributable to
contaminating immunocytes is speculation based upon local
pathological advice and is supported by the lack of inflammatory
infiltrates in any of the post mortem samples (Figures 5.1 & 5.2).
Thirdly, it is impossible to be certain whether the PCR technique
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used in this study amplified all variants of HIV to an equal extent.
This could have caused false negative results.
Variation of the HIV genome occurs within and amongst
individuals (Hahn et al 1986, Simmonds et al 1990b). This may
represent an evolutionary response by the virus as a means of
evading the immune system (Simmonds et al 1990b). However, in
this study, myocardial infiltration by HIV was determined not on
the basis of an absolute concentration of the virus but instead by
means of the ratio of viral concentrations in heart and peripheral
blood lymphocytes from the same individual. Peripheral blood
lymphocytes were drawn within six months of the post mortem
reducing the likelihood of substantial HIV genomic differences
between these cells and the myocardial tissue.
Ironically, this slow ongoing genomic variation offers a means of
confirming the results of this study. HIV extracted from the heart
may have a subtle difference in base pair sequence compared to
other variants of the virus obtained from different organs such as
lymph node or spleen confirming cardiac infiltration as opposed to
contamination with infected immunocytes. Donaldson et al (1994)
have shown that patients with AIDS have widespread dissemination
of the virus compared with individuals with early infection in
whom HIV is confined to the cells of the immune system.
Moreover, it is recognised that HIV strains recovered from the
brain or intestine of patients with neurological or gastrointestinal
disease respectively can be distinguished from those found in
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peripheral blood cells based upon a preferential growth in
macrophages, a lack of cytopathic properties in T lymphocytes and
a reduced sensitivity to serum neutralisation (Levy 1990).
5.7 CONCLUSIONS
This study shows that HIV infected patients can, in some cases,
have substantial concentrations of HIV within the myocardium and
that this may be associated with heart muscle disease. The
apparent lack of viral replication within the heart indicates that




REDUCED SERUM SELENIUM CONCENTRATIONS AND
HIV HEART MUSCLE DISEASE
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6.1 SUMMARY
Keshan disease is a form of cardiomyopathy associated with
selenium deficiency which occurs in certain mountainous parts of
China. Patients infected with HIV also suffer from selenium
deficiency and are susceptible to various forms of cardiac
dysfunction.
The purpose of this study was to investigate the relationship
between serum selenium concentration and the development of
heart muscle disease in HIV patients. Thirty patients with HIV
heart muscle disease and an equal number of HIV positive controls
with echocardiographically normal hearts matched for age, sex,
stage of disease, risk group and body mass index were studied.
Serum selenium concentrations were determined using carbon
furnace atomic absorption and were shown to fall below the
reference interval in 49 out of 60 patients (81.7%). Patients with
heart muscle disease, particularly those with dilated
cardiomyopathy and isolated right ventricular dilation, had non¬
significant trends towards lower selenium values compared with
matched controls, median values 0.44 vs 0.50 /xmol/l and
0.38 vs 0.58 jumol/1 respectively.
Selenium deficiency appears to be widespread in patients with HIV
infection and may contribute to the development of heart muscle
disease in this condition.
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6.2 INTRODUCTION
HIV heart muscle disease is manifest as dilation and/or dysfunction
of either or both ventricles and some patients develop severe
cardiac failure (Herskowitz et al 1993a). To date, the precise cause
of these phenomena is unknown although several pathogenetic
mechanisms have been proposed. These include direct damage to
the myocardium by HIV, indirect damage secondary to
immunological mechanisms, infection with opportunistic organisms
known to cause myocarditis (a putative precursor of heart muscle
disease), drugs used in the treatment of HIV disease and its
complications and nutritional deficiencies (Acierno 1989,
Herskowitz and Baughman 1994).
Heart muscle disease in HIV infection may be analogous to Keshan
disease, a naturally occurring cardiomyopathy associated with
selenium deficiency. This occurs because rural peasants
particularly in mountainous areas have a monotonous, limited diet
consisting of grains with a low selenium content (Keshan Disease
Research Group 1979, Levander 1986). Foods which are rich in
selenium include organ meats, muscle meats and seafoods. Grains
and cereals contain variable amounts of selenium and fruits and
vegetables are mostly poor sources (Levander 1986).
Keshan disease is reversible and its incidence has fallen
dramatically after widespread dietary supplementation with
107
selenium (Keshan Disease Research Group 1979). This offers the
prospect of similar treatment for HIV patients with established
heart muscle disease or prophylactic therapy for those who may be
at risk of developing the condition.
HIV infected patients are prone to deficiencies of micronutrients
including zinc, folate and B group vitamins. This is associated with
impairment of immune function and progression of HIV disease
(Kotler 1992, Singer et al 1992). Plasma (Mantero-Atienza et al
1991) and erythrocyte (Dworkin et al 1988) selenium
concentrations have been reported as being reduced in HIV
patients. Furthermore, Dworkin et al (1989) demonstrated that
eight AIDS patients without overt cardiac dysfunction had
significant myocardial selenium depletion when compared to nine
non-AIDS patients with normal hearts. There has also been an
isolated report of cardiac function improving in HIV patients
following dietary supplementation with selenium (Zazzo et al
1988). To date, however, there has been no work showing
conclusively that a cause and effect relationship exists.
The aims of this study were firstly to establish the prevalence of
selenium deficiency in HIV patients and secondly to determine
whether this was associated with cardiac dysfunction.
6.3 SUBJECTS AND METHODS
Patients with HIV infection participating in an prospective
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echocardiographic study who were found to have heart muscle
disease were selected on the basis of availability of matched
controls from within the cohort. A total of 60 HIV patients were
chosen, 30 with heart muscle disease and the remainder with
structurally normal hearts. Heart muscle disease patients and
controls were matched for age (within 15 years), sex, risk group
(homosexual or injection drug user), stage of disease as reflected by
CD4 count (within 120 cells//d) and body mass index (within
20%).
6.3.1 Echocardiography
Three independent observers (including the operator) analysed
two dimensional and M-mode images obtained using a Hewlett
Packard Sonos 100 machine. Three distinct forms of heart muscle
disease were identified:
a) Dilated cardiomyopathy: global hypokinesia of the left ventricle
reported by all three observers together with a fractional shortening
of less than 28%.
b) Borderline left ventricular dysfunction: dilated cardiomyopathy
reported by only one or two of the three observers or left
ventricular end-diastolic diameter more than 58 mm together with a
fractional shortening of 28% or above.
c) Isolated right ventricular dilation: right ventricle larger than
the left on standard two dimensional views and normal left
109
ventricular function.
6.3.2 Serum selenium assay
Blood was drawn either at the time of or within one month of
echocardiography. Samples were allowed to clot and then spun at
3000 rpm for 10 minutes in order to separate the serum which was
then stored at -70°C. Immediately prior to analysis, the serum
samples were thawed and then heated at 55°C for 20 minutes in a
water bath in order to inactivate any virus that was present.
Thereafter, the samples were frozen again and transported in dry
ice to the laboratory where selenium assay was performed using
carbon furnace atomic absorption. Calibration was by standard
additions using a palladium modifier. Appropriate internal and
external quality assurance samples were analysed with each batch
of samples. The coefficient of variation was 5% for selenium
concentrations of 0.5 jumol/1 or more and 10% for smaller
concentrations (Fell - personal communication). The normal
reference interval (0.8 - 1.4 /jlmol/1) was derived from a mixed
population of healthy laboratory staff aged 60 years or less (Fell -
personal communication).
In order to confirm that the repeated freezing and thawing cycles
and subsequent heat inactivation were not adversely affecting the
accuracy of the selenium assay, a sample of blood from a healthy,
non-HIV positive individual was split into several aliquots and
analysed after being exposed to different permutations of these
procedures.
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Statistical differences between patients and controls were calculated
using Mann Whitney U tests supplied as part of the Minitab
package run on an IBM compatible personal computer.
6.4 RESULTS
The baseline characteristics of the patient and control groups are
summarised in Table 6.1. Thirty cases of heart muscle disease and
an equal number of suitable controls were identified only after
studying 173 patients from the cohort of 240. Of those with
cardiac abnormalities, 12 had dilated cardiomyopathy, 11
borderline left ventricular dysfunction and seven isolated right
ventricular dilation. There were no significant differences between
heart muscle disease patients and controls in terms of age, stage of
disease and body mass index.
Figure 6.1 shows the serum selenium concentrations in the patient
and control groups for each type of heart muscle disease. The most
striking finding was that the majority of HIV patients (49/60) had
serum selenium concentrations which fell below the reference
interval. This occurred both in patients suffering from heart
muscle disease and in those with structurally normal hearts. As a
group, the heart muscle disease patients had a median serum
selenium concentration of just 0.45 /xmol/1, not significantly
different from the 0.55 ^rnol/1 found in the controls, but well below

































































































































































































dilated cardiomyopathy or isolated right ventricular dilation had
non-significant trends towards lower serum selenium concentrations
compared with their matched controls, the difference being most
marked in the latter group; median values 0.44 vs 0.50 /xmol/1 and
0.38 vs 0.58 /rniol/1 respectively. Serum selenium concentrations
were non-significantly higher in the borderline left ventricular
dysfunction patients compared with their controls, median values
0.59 vs 0.54 /miol/1 respectively.
6.5 DISCUSSION
The precise aetiology of heart muscle disease in patients with HIV
infection is unknown and is likely to be multifactorial. Relatively
little attention has been paid to the possible pathogenetic role of
micronutrient deficiency.
HIV patients suffer from several deficiency states including B
group and fat soluble vitamins, folate, zinc and selenium (Kotler
1992). These occur predominantly as a result of reduced intake and
intestinal malabsorption (Kotler 1989). Reduction in intake is
attributable to lesions of the upper gastrointestinal tract such as oral
candidiasis and anorexia associated with drug treatment and the
effects of cytokines such as TNF-o; whose serum concentrations
are related directly to the stage of HIV disease (Lahdevirta et al
1988). Cardiac dysfunction occurs predominantly in late stage HIV
infection when TNF-a concentrations are at their highest. Small
intestinal and colonic injury by opportunistic organisms and
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possibly HIV itself can cause malabsorption (Kotler 1989). These
complications may occur singly or in combination and are
potentiated by recurrent infection to which HIV patients are
particularly prone.
Weight loss and deficiency states are associated with functional
impairment, cognitive loss and damage to organs including the
immune system (Kotler 1992). Immunological dysfunction is
manifest as impairment of the lymphocyte proliferation response to
mitogenic stimulation and a fall in natural killer cell cytotoxicity
(Baum et al 1991a, Baum et al 1991b).
There is a tendency for body weight to fall as HIV disease becomes
more advanced, the risk of death increasing considerably once it
has reached less than two-thirds of the ideal (Kotler 1992). This
decline in weight with advancing HIV disease is neither inevitable
nor necessarily progressive. Indeed, it is potentially reversible by
aggressive treatment of secondary infections and enteral and
parenteral administration of an elemental diet (Kotler 1992, Singer
et al 1992). The steroid megestrol promotes appetite and weight
gain as does zidovudine, albeit on a less predictable basis (Kotler
1992). Cannabis has also been used to enhance appetite. There is
evidence that as body weight increases and specific vitamin and
trace element deficiencies are corrected, improvements in immune
function occur together with enhancement of cognitive function and
of wellbeing (Baum et al 1991a, Baum et al 1991b, Kotler 1992,
Singer et al 1992).
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Micronutrient deficiency states have been implicated in other forms
of cardiovascular disease. Low red cell and toenail concentrations
of selenium are associated with increased risk of acute myocardial
infarction (Kok et al 1989). Experiments in mice suggest that
selenium depletion predisposes to greater myocardial necrosis in the
context of Coxsackie B4 viral infection (Jin et al 1980). However,
the most compelling evidence linking selenium deficiency to heart
muscle disease is found in China where Keshan disease has been
virtually eliminated by mass dietary supplementation with this trace
element (Keshan Disease Research Group 1979).
The basis for this practice originates from a study of over 10 000
one to nine year old children in the Sichuan province of China
(Keshan Disease Research Group 1979). This population used to
have an extremely low blood selenium concentration of less than
0.1 /xmol/1. In 1974, the children were divided randomly into two
groups, one receiving regular sodium selenite and the other
placebo. Dosage regimes were based upon the ease of
administration, lack of side effects (other than nausea and
dyspepsia) and the absence of gross physical changes and abnormal
liver function tests in previous studies. Compliance in the treatment
group was 98.9%. By the end of the year, 13.5% of the controls
had evidence of Keshan disease compared to just 2.2% of the
treated group, this difference being strongly statistically significant.
One year later, the respective figures were 9.5% and 1% and the
decision was made to treat all the children with sodium selenite. At
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the end of 1976, just four children out of 12 579 (0.32%) were
suffering from Keshan disease compared to an annual incidence of
about 10% in 1973 before the start of the dietary supplementation
programme. Moreover, out of 107 children with Keshan disease in
the control group, 53 died and six remained in overt cardiac
failure. This was in striking contrast to the outcome in 21 cases of
Keshan disease in the sodium selenite treated group; only three
children died, one remained in heart failure and 17 regained normal
cardiac function. Unfortunately, blood selenium concentrations
were not assayed after supplementation.
This work showed conclusively that low blood selenium was
associated with Keshan disease and that supplementation with
sodium selenite not only reduced the incidence of the condition but
could also restore cardiac function to normal.
The hearts of AIDS patients ostensibly without cardiac dysfunction
have been shown to be deficient in selenium compared to those of
non-HIV positive controls with structurally normal hearts (Dworkin
et al 1989). However, this finding emanated from a retrospective
post mortem study where cardiac function was judged to be normal
solely on the basis of casenote analysis and assessment of
radiological cardiothoracic ratios.
Zazzo et al (1988) described eight patients with reduced plasma
selenium and impaired left ventricular function estimated using
echocardiography. The cardiac function of six of these patients
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reverted to normal 21 days after starting treatment with oral
sodium selenite. This study had several important methodological
flaws, however. The diagnosis of cardiomyopathy was made
exclusively using echocardiography with the result that potentially
self-limiting conditions such as myocarditis may have been
misdiagnosed. Moreover, red cell glutathione peroxidase activity
(see below) was normal in all patients despite low plasma
concentrations of selenium. This suggests that the whole body
selenium content was normal and that the reduction in plasma
concentrations reflected a reversible acute phase phenomenon.
Finally, the study was neither double blind nor placebo controlled.
Despite these criticisms however, such studies provide
circumstantial evidence implicating selenium deficiency in the
pathogenesis of HIV heart muscle disease.
Glutathione peroxidase represents a potential link between selenium
deficiency and heart muscle disease. This selenoenzyme acts as a
major scavenger of free radicals which would otherwise cause
significant tissue damage, and its activity is related closely to the
blood concentration of selenium, particularly in situations of
marginal micronutrient intake (Thomson et al 1977). Patients with
HIV infection have been found to have reduced glutathione
peroxidase activity within the blood (Dworkin et al 1988).
Moreover, such patients have excessive free radical production,
possibly as a result of their increased metabolism (Revillard 1991).
The combination of these factors could render them particularly
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vulnerable to end-organ damage.
The results of this study indicate that selenium deficiency is
widespread in patients with HIV infection, irrespective of their state
of health or stage of disease. Even control patients who were
clinically well and not suffering overtly from intercurrent infection
or end-organ damage had serum selenium concentrations which
were well below the normal range although not as low as those
observed in patients with Keshan disease. This is in keeping with
the observation that asymptomatic HIV patients at an early stage of
the disease suffer from subclinical deficiency states (Mantero-
Atienza et al 1991). Many patients with significant serum selenium
depletion and/or heart muscle disease had normal or near normal
body mass indices. This suggests that weight loss per se is not a
major contributory factor in the development of either HIV related
heart muscle disease or selenium deficiency. It follows also that an
HIV patient with normal body weight cannot be assumed to be
either nutritionally replete or free from cardiac dysfunction.
6.6 LIMITATIONS OF THE STUDY
The concentration of selenium within the serum reflects short term
intake which may not be representative of the usual steady state
value. For example, it is thought that the concentration of serum
selenium may fall acutely in response to intercurrent infection
(Mantero-Atienza et al 1991). Although the majority of patients did
not appear to be acutely unwell, subclinical secondary infection
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could have reduced their serum selenium concentration, giving a
falsely low indication of their long term selenium status. A more
accurate assessment of long term selenium status would have been
obtained by assaying nail clippings (Kok et al 1989).
The finding that HIV patients with isolated right ventricular dilation
had the lowest concentration of serum selenium supports the theory
that this parameter may fall in response to acute illness. Many
patients with isolated right ventricular dilation are not suffering
from heart muscle disease but rather from the effects of right-sided
pressure overload secondary to pulmonary hypertension induced by
respiratory infection or multiple pulmonary emboli (Himelman et al
1989b) (see Section 1.12). These conditions may cause an acute
phase reduction in the concentration of serum selenium rendering
spurious any apparent link between isolated right ventricular
dilation and low serum selenium concentrations.
It is also difficult to be certain how well serum and myocardial
concentrations of selenium correlate, although a close relationship
has been demonstrated in patients with ischaemic heart disease
(Oster et al 1989). The only practical solution to this problem
would have been to obtain cardiac tissue by means of
endomyocardial biopsy whenever this was indicated clinically.
This study nevertheless, provides circumstantial evidence of an
association between selenium deficiency and HIV heart muscle
disease and it raises the possibility that other deficiency states may
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be implicated.
The widespread reduction in serum selenium concentration in HIV
patients which has been shown in this and other work is unlikely to
occur in isolation. Multiple micronutrient deficiencies are more
probable as evidenced by a study in New York (Dworkin et al
1990) where 43 patients suffering from AIDS, AIDS related
complex or HIV seropositivity per se completed food diaries. It
was found that almost 90% of each group were ingesting less than
50% of the recommended daily allowance for at least one nutrient.
The mean number of deficiencies per patient were 1.8 in AIDS, 3.8
in AIDS related complex and 2.9 in HIV seropositive only cases.
The concentrations of other antioxidants including vitamins A, C
and E and beta-carotene therefore merit assessment in order to
determine their potential contribution to the pathogenesis of HIV
heart muscle disease.
Keshan disease is both reversible and preventable (Keshan Disease
Research Group 1979). Some forms of immune dysfunction
associated with nutritional deficiency in HIV patients also appear to
be potentially reversible with dietary supplementation (Kotler 1992,
Baum et al 1991a, Baum et al 1991b). It is possible therefore, that
myocardial damage is remediable and that dietary supplementation
with micronutrients initiated at an early stage in HIV infection may
prevent or retard the development of cardiac dysfunction.
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6.7 CONCLUSIONS
A low concentration of serum selenium is widespread in patients
with late stage HIV infection irrespective of their apparent
wellbeing. HIV patients with heart muscle disease appear
particularly likely to suffer from selenium deficiency, although no
causative link has yet been established. Speciation of the forms of
selenium in plasma, red cell and plasma glutathione peroxidases,
together with an assessment of the concentration of this trace
element in the tissues might give a more definitive evaluation of the
true selenium status in HIV patients.
This study establishes the need for a comprehensive assessment of
the nature and extent of nutritional deficiencies in HIV infection in
order firstly to determine whether they contribute to the
pathogenesis of heart muscle disease and secondly to provide a
rational basis for the use of dietary supplements.
CHAPTER 7




To date, there is very little information about the effect of heart
muscle disease upon survival in HIV infected patients. There is
anecdotal evidence that individuals with dilated cardiomyopathy
have a particularly poor prognosis but it is unclear whether this is
due to cardiac dysfunction or advanced HIV disease per se. A
prospective echocardiographic survey spanning four years was
therefore undertaken to determine the time to death from the index
echocardiogram for HIV patients with various types of cardiac
dysfunction and to compare this with individuals at the same stage
of HIV disease who had structurally normal hearts.
Two hundred and ninety-six adults infected with HIV, mean (range)
age 32.7 years (21.5 - 67.6 years) drawn from all the major risk
groups for HIV infection in the UK underwent serial
echocardiographic assessment. Abnormal cardiac function was
identified in 44 (14.8%) patients. Thirteen (4.4%) were found to
have dilated cardiomyopathy, 19 (6.4%) had borderline left
ventricular dysfunction and 12 (4%) had isolated right ventricular
dilation. The majority of patients with dilated cardiomyopathy had
CD4 counts of less than 100 cells//d indicating late stage HIV
disease. During the period of study, 12/13 (92%) subjects with
dilated cardiomyopathy, 8/19 (42%) patients with borderline left
ventricular dysfunction and 5/12 (41%) patients with isolated right
ventricular dilation died of AIDS related conditions. Kaplan Meier
survival curves were calculated and Cox regression was used to
122
adjust for CD4 counts. The median survival from the index
echocardiogram was just 101 days (95% CI 42 - 146 days) for the
dilated cardiomyopathy group. This was significantly less than not
only those patients with echocardiographically normal hearts, but
also a subgroup of control patients with structurally normal hearts
and extremely low CD4 counts of less than 20 cells//d who
survived for 472 days (95% CI 383 - 560 days). However,
survival was not significantly different for subjects with either
borderline left ventricular dysfunction or isolated right ventricular
dilation compared with their counterparts with normal
echocardiographic findings.
The present study is the first to establish the effects of the various
forms of HIV heart muscle disease upon survival. Even after
adjusting for the significantly reduced CD4 count with which
dilated cardiomyopathy is associated, the outlook for these
individuals is particularly poor. Borderline left ventricular
dysfunction and isolated right ventricular dilation do not carry
adverse prognostic implications.
7.2 INTRODUCTION
More patients with HIV disease are now surviving previously fatal
opportunistic infections, only to succumb to neoplasia or end-organ
damage (Peters et al 1991). Heart muscle disease is one such
complication and seems destined to become a significant cause of
cardiac failure around the world. The natural history of HIV heart
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muscle disease has not yet been established, largely because most
published work has been based on small or cross sectional surveys
(see Section 1.11.1). There is anecdotal evidence that patients with
significant impairment of left ventricular function have a poor
prognosis (Monsuez et al 1988, Himelman et al 1989a, Kinney et al
1989, Blanchard et al 1991), but this has yet to be confirmed by a
formal survival study.
A cohort of HIV positive individuals was studied prospectively in
Edinburgh for almost four years. The majority attended a single
centre where detailed records were kept including date and cause of
death. Some patients, including all those who died unexpectedly in
the community, underwent post mortem examinations and the
results were made available by prior agreement of the pathologists
concerned and the Regius Professor of Forensic Medicine. In this
way, it was possible to compare the time from the echocardiogram
to AIDS related death (as opposed to other causes including trauma
and overdose) for heart muscle disease patients and controls. By
using Cox regression analysis to allow for any differences between
the two groups such as CD4 count and CDC classification, the
effect upon prognosis attributable solely to the various forms of
heart muscle disease was established.
7.3 SUBJECTS AND METHODS
Over a four year period, 296 HIV positive patients from all the
major risk groups for HIV infection in the UK (203 injection drug
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users, 59 homosexuals, 28 heterosexuals, three blood product
recipients and three with multiple risk factors), underwent serial
echocardiographic assessment. The majority of these patients
(230/296) were participating in the prospective study described in
Chapter 3, 10 individuals being excluded for methodological
reasons. The additional 66 patients were recruited by Dr Peter
Currie as part of the ongoing HIV heart muscle disease project
funded by the British Heart Foundation. Dr Currie was also
responsible for the bulk of the statistical analysis aided by Dr R A
Elton of the Medical Statistics Department at the University of
Edinburgh.
Within this expanded cohort, 112 patients were diagnosed as
suffering from AIDS, 102 were classed as group IV without AIDS,
50 were CDC group III and 11 had asymptomatic HIV infection.
A contemporary classification was not available in 21 cases.
7.3.1 Echocardiography
The methodology of the ultrasound examinations is described in
Chapter 3.
7.3.1.1 Definitions:
Dilated cardiomyopathy - a fractional shortening of less than 28 %
together with global left ventricular hypokinesia reported by all
three observers.
Borderline left ventricular dysfunction - left ventricular end-systolic
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diameter of more than 58 mm with preserved systolic function
(fractional shortening less than 28%), or global left ventricular
dysfunction reported by only one or two of the three observers.
Isolated right ventricular dilation - right ventricular size greater
than that of the left ventricle on standard two dimensional views
and normal left ventricular systolic function.
7.3.2 CD4 counts and clinical information
CD4 counts were obtained by lymphocyte immunophenotyping
using a Becton Dickinson FACScan™ flowcytometer. Information
on the clinical status of each patient and, where appropriate, the
cause and date of death was obtained from hospital case records
and post mortem reports.
7.3.3 Statistical methods
The primary end point was mortality from an AIDS related
condition and survival times were censored at death from other
causes. Survival curves were obtained using the Kaplan Meier
estimate and Cox proportional hazards regression (BMDP software)
was used to compare the three heart muscle disease groups with the
remainder of the cohort who had normal echocardiograms.
The association between CD4 counts and cardiac complications was
assessed using the Mann-Whitney U test. A p value of less than
0.05 was taken as indicating a result of statistical significance.
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7.4 RESULTS
The mean CD4 count of patients undergoing echocardiographic
assessment was 153 cells//d (range 0 - 1178 cells/ju,l). Over 90%
(268/296) of patients showed evidence of immunosuppression with
a CD4 count of less than 400 cells/jul. This included 146 patients
whose CD4 count was less than 100 cells//d indicating advanced
HIV disease.
Echocardiographic evidence of cardiac dysfunction was found in a
total of 44 patients. Dilated cardiomyopathy was demonstrated in
13 patients, borderline left ventricular dysfunction in 19 and
isolated right ventricular dilation in 12.
One hundred and twenty-three patients died during the period of
study. Ninety-nine deaths were attributable to an AIDS related
condition and the remaining 24 cases were accounted for by other
causes including hepatitis (nine patients) and drug overdose (six
patients).
CD4 counts were significantly lower in the dilated cardiomyopathy
patients compared with the other three groups. There was no
significant difference, however, in the CD4 values of patients with
borderline left ventricular dysfunction and isolated right ventricular
dilation compared with those with structurally normal hearts (Table





















































that dilated cardiomyopathy patients have significantly more
advanced HIV disease than any other group.
In order to draw valid conclusions about the effect of various forms
of heart muscle disease on survival, Cox regression analysis was
used to correct for the CD4 count in addition to CDC status, age,
sex, time difference between echocardiogram and CD4 count and
risk group. Figure 7.1 shows survival curves to AIDS related
deaths for each group. Patients with dilated cardiomyopathy had a
significantly poorer outlook compared with those with structurally
normal hearts (A2 = 23.43, p < 0.001, hazard ratio 11.68, 95%
CI 4.32 - 31.58). In contrast, the survival of patients with
borderline left ventricular dysfunction and isolated right ventricular
dilation did not differ significantly from that of individuals without
evidence of cardiac disease (hazard ratios 1.17, 95% CI 0.51 - 2.70
and 1.48, 95% CI 0.56 - 3.95 respectively).
Figure 7.2 shows the survival curves for patients with CD4 counts
of less than 20 cells/yu.1. The excess mortality in patients with
dilated cardiomyopathy remained significant even when analysis
was restricted to a subgroup of 59 individuals with structurally
normal hearts and CD4 counts of less than 20 cells/^1 (Figure 7.2),
and also when deaths from all causes were assessed. Median
(95% CI) survival to AIDS related death was 101 days
(42 - 146 days) in the 13 patients with dilated cardiomyopathy
compared with 472 days (383 - 560 days) in the 59 individuals with






























































































20 cells/yu.1. Finally, the survival of the dilated cardiomyopathy
group was reduced significantly compared with a subset of 13
patients with structurally normal hearts (median survival 407 days)
who were matched individually for age, sex, risk factor for HIV
infection and CD4 count.
7.5 DISCUSSION
Although several echocardiographic and autopsy studies have
described heart muscle disease associated with HIV infection (see
Section 1.11.1), there is scant information about the natural history
of this condition. Dilated cardiomyopathy appears to be associated
with a poor prognosis (Monsuez et al 1988, Himelman et al 1989a,
Kinney et al 1989, Blanchard et al 1991) based upon anecdotal
reports. No definitive work, however, has been published where
the prognostic significance of all forms of HIV heart muscle disease
including borderline left ventricular dysfunction and isolated right
ventricular dilation has been evaluated.
The results of this study confirm that the natural history of patients
with dilated cardiomyopathy is an early death from an AIDS related
condition. This seems to be independent of the CD4 count at the
time of their index echocardiogram. The outlook for patients with
other forms of HIV heart muscle disease is much less gloomy and
may reflect the potentially reversible nature of these conditions. It
has been shown in Chapter 3 that some cases of borderline left
ventricular dysfunction resolve spontaneously suggesting that this
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may be caused by a self-limiting myocarditis which does not
progress to irreversible cardiac failure. Isolated right ventricular
dilation may also be transient and is probably related to pulmonary
hypertension associated with parenteral drug use or recurrent
bronchopulmonary infection rather than primary myocardial disease
(see Section 1.12 and Chapter 3).
Establishing a diagnosis of cardiac failure due to HIV heart muscle
disease is worthwhile because immediate treatment can be offered.
Moreover, it may be possible to reduce the long term morbidity
and mortality attributable to this condition. Multicentre studies of
non-HIV infected patients with left ventricular impairment due to
other causes such as ischaemic heart disease (The CONSENSUS
Trial Study Group 1987, Pfeffer et al 1992, The SOLVD
Investigators 1992) have shown that vasodilators not only reduce
morbidity and the frequency of hospitalisation for cardiac failure,
but also prolong life. HIV patients with overt cardiac failure may
merit treatment with conventional agents such as diuretics and ACE
inhibitors (see Chapter 3). There are, however, some individuals
with low systemic vascular resistance where afterload reduction
with ACE inhibitors may be deleterious (Herskowitz and Baughman
1994).
There are as yet no trials which have evaluated the long term
benefits of vasodilator therapy in HIV patients either with heart
failure due to dilated cardiomyopathy or in those with
asymptomatic left ventricular dysfunction.
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One of the difficulties in evaluating mortality due to HIV heart
muscle disease is the apparent reluctance to ascribe death directly to
circulatory failure. There is a tendency to under diagnose cardiac
complications even in the face of convincing post mortem evidence
(Cammarosano and Lewis 1985, Stewart et al 1989, Lewis 1989).
In this series, left ventricular failure was rarely reported as a cause
of death even for patients with dilated cardiomyopathy. This was
undoubtedly a contributory factor in many cases but may have been
overlooked as the features of heart failure are often attributed
mistakenly either to anaemia or to the opportunistic pulmonary
infections which are common in HIV patients (Fink et al 1984,
Corallo et al 1988, Lipshultz et al 1989, Stewart et al 1989).
"AIDS related conditions" in the Edinburgh cohort usually meant
bronchopneumonia or Pneumocystis carinii pneumonia, or
end-organ failure such as HIV encephalitis. Any prospective study
of the role of anti-failure therapy in HIV patients will therefore
have to include careful autopsy evaluation of the direct cardiac
contribution to death.
The most dramatic result of this study is the finding that the group
with dilated cardiomyopathy had a significantly shorter lifespan
than even those patients with CD4 counts of less than
20 cells/yu.1 and normal echocardiograms. In this group of highly
vulnerable individuals with end-stage HIV disease, the presence of
dilated cardiomyopathy has been shown to confer a significantly
worse outlook.
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Dilated cardiomyopathy in HIV infection appears therefore to be an
independent, adverse prognostic factor. Other conditions with
prognostic significance include oral candidiasis, hairy leucoplakia,
disseminated herpes zoster and constitutional symptoms. These
are all associated with an increased risk of progression from
asymptomatic HIV infection to AIDS (Klein et al 1984, Greenspan
et al 1987, Melbye et al 1987, Moss et al 1988). More recently, it
has been shown that low socioeconomic status is also significantly
associated with increased mortality in HIV infected patients (Hogg
et al 1994).
The results of the Concorde trial indicate that it is inappropriate to
rely solely on the CD4 count when assessing the need for
antiretroviral treatment or the long term prognosis of HIV positive
patients (Concorde Coordinating Committee, 1994). Although the
decline in CD4 count correlates well with disease progression in
population studies (Goedert 1987, De Wolf et al 1988, Moss et al
1988), there can be a wide variation within individual patients of
both the absolute value and the rate of cell loss over time, thus
reducing the predictive power of this parameter. Given that dilated
cardiomyopathy has now been established as an independent
prognostic factor, therapeutic decisions in HIV patients should be
made in the context not only of serological results but also of
clinical factors including the presence of heart muscle disease.
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7.6 CONCLUSIONS
Cardiac involvement in HIV infection is important for three
reasons. Firstly, it is possible that HIV heart muscle disease will
become a major cause of cardiac failure in the early part of next
century. This follows from the WHO prediction that up to 40
million people will be infected with HIV by the year 2000 (WHO
press release, WHO/30, 10 April 1994), the observation that fewer
individuals are dying of opportunistic infection and malignancy
(Peters et al 1991) and the finding that approximately 6.2% of
patients with late stage HIV disease develop heart failure
(Herskowitz et al 1993a). Secondly, dilated cardiomyopathy has
now been shown to be an independent, adverse prognostic factor
which, if nothing else, should influence therapy and indeed the
overall management of patients. Finally, although the outlook for
individuals with dilated cardiomyopathy is clearly very poor,
palliative treatment may confer symptomatic benefit and enhance
the quality of life. The possibility that conventional anti-failure
therapies may help to prolong life in these patients merits further





This work has helped to establish that heart muscle disease is the
most important cardiac manifestation of HIV infection and
emphasises that this may result in cardiac failure and death. The
combination of a dramatic increase in the spread of HIV infection
and the increasing likelihood of patients surviving to develop
end-organ damage means that there will be a large number of
people potentially susceptible to heart muscle disease in the early
part of the next century. HIV heart muscle disease, therefore, looks
set to become a major cause of cardiac failure around the world
within the next twenty years.
Much of the current knowledge about HIV heart muscle disease
comes from small, cross-sectional studies and anecdotal reports.
The aetiology of the condition is unknown but is likely to be
multifactorial. The absence of large, prospective studies has
resulted in a dearth of information about whether the various forms
of cardiac dysfunction are progressive or reversible and also how
each of these conditions affects prognosis.
This prospective echocardiographic study has followed 296 patients
for four years. The associated demographic, clinical,
haematological and therapeutic information was well documented
and accurate information about the cause of death was provided by
an autopsy service which also helped to create an extensive library
of deep frozen tissue for retrospective analysis.
The study was conducted in a city where approximately 1 in 150
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people aged between 15 and 35 are thought to harbour the virus
(Brettle 1990). Edinburgh HIV patients are drawn from all risk
groups and have been reviewed since the mid-1980's at a single
clinic with a low default rate (Brettle et al 1994).
A total of 34 out of 240 HIV patients were found to have heart
muscle disease on their index echocardiogram, a prevalence of
14.2%. Three principal forms of HIV heart muscle disease were
identified - dilated cardiomyopathy, borderline left ventricular
dysfunction and isolated right ventricular dilation.
Thirteen patients had dilated cardiomyopathy. Their median CD4
count was just 10 cells/^il, significantly lower than that of all the
other groups and indicative of the profound immunosuppression
associated with end-stage HIV disease. The mode of acquisition of
the virus did not appear to be important since dilated
cardiomyopathy was found in injection drug users, homosexuals
and haemophiliacs. Borderline left ventricular dysfunction and
isolated right ventricular dilation occurred at an earlier stage of
HIV infection as evidenced by CD4 counts which were not
significantly different compared with those patients with normal
echocardiograms. Isolated right ventricular dilation occurred
almost exclusively amongst injection drug users.
Dilated cardiomyopathy was invariably irreversible and usually
undiagnosed prior to the echocardiogram despite the fact that the
majority of patients had symptoms and/or signs that were
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compatible with heart failure. Some individuals achieved
symptomatic relief subsequently after receiving treatment with
diuretics and ACE inhibitors.
In contrast, two out of eight patients with borderline left
ventricular dysfunction who underwent repeat echocardiography
reverted to normal, suggesting that this might have been due to a
self-limiting myocarditis. Most of these patients also had
symptoms potentially attributable to the cardiovascular system, but
only a minority had objective clinical evidence of heart failure.
Reversibility was found also in five out of the eight cases of
isolated right ventricular dilation where repeat echocardiography
was performed. This condition was often associated with a
respiratory tract infection. Other causes such as pulmonary
hypertension attributable to emboli within the lungs or tricuspid
valvular incompetence due to previous endocarditis were also
identified. Isolated right ventricular dilation is therefore due
usually to pressure or volume overload of the right ventricle rather
than to a true myopathic process. Thus, although the majority of
these patients complained of breathlessness, this was probably a
reflection of an intercurrent respiratory tract infection rather than
underlying cardiac disease.
The incidence of heart muscle disease was found to be 4.23% per
patient-year, slightly less than a comparable but much smaller
survey performed in the USA (Herskowitz et al 1993a). Several
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factors could have accounted for this including differences in
demography, the provision of adjunctive treatment and the intensity
of follow up visits between the two patient populations. The
recognised trend of a lengthening interval from the diagnosis of
AIDS to death may also have been relevant (Peters et al 1991,
Rutherford 1994).
Possible causes of heart muscle disease include secondary infection
with the cardiotropic organisms Toxoplasma gondii and
cytomegalovirus which are found commonly in HIV patients,
infiltration of the myocardium by HIV itself, and nutritional
deficiencies (Acierno 1989, Herskowitz and Baughman 1994).
Each of these factors was considered in turn.
Serological analysis of a subgroup of 173 patients in the Edinburgh
cohort showed that there was no excess of patients in any of the
heart muscle disease groups who had been or were actively infected
with either Toxoplasma gondii or cytomegalovirus. Moreover,
there were some patients in all the heart muscle disease groups who
had never been exposed to either agent. Although the reliability of
serological analysis in patients with profound immune deficiency is
open to question, these results do suggest that secondary infection
with Toxoplasma gondii and cytomegalovirus are not in themselves
responsible for heart muscle disease. However, these organisms
could still act as cofactors rather than direct mediators of cardiac
damage.
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Zidovudine causes a dose dependent, reversible skeletal myopathy
(Fischl 1989, Dalakas et al 1990, Berger et al 1991), and it has
been implicated in the pathogenesis of HIV heart muscle disease
(Herskowitz et al 1992). In order to test this hypothesis, a
retrospective analysis was performed on the subgroup of 173
patients mentioned above. It was found that the proportions of
patients treated with this drug in each of the heart muscle disease
categories were similar and no different to the group without
cardiac dysfunction. Moreover, there were patients in each of the
heart muscle disease groups who had never received zidovudine.
The cumulative dose of zidovudine received by patients in the
borderline left ventricular dysfunction and isolated right ventricular
dilation groups was significantly greater than in the group with
structurally normal hearts. This may have arisen because patients
in these two heart muscle groups had a variety of symptoms which
may have prompted their attending physicians to be more rigorous
in their efforts to prescribe antiretroviral treatment in the hope of
retarding the progression of HIV disease.
Thus, although this study has provided circumstantial evidence
which militates against a direct role for zidovudine in the
pathogenesis of heart muscle disease, its contribution as a cofactor
remains possible.
The role of HIV infiltration of the myocardium in the pathogenesis
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of HIV heart muscle disease was investigated using the polymerase
chain reaction. All but one of a group of 12 patients with and
without heart muscle disease had HIV present within the
myocardium. In some cases, this was at a concentration far in
excess of that within circulating lymphocytes, the usual target cell
of the virus. Although those individuals with dilated
cardiomyopathy had the highest myocardial concentrations of the
virus, this failed to achieve statistical significance.
Monoclonal antibodies to HIV p24 and group 120 antigens were
employed to look for evidence of viral replication within frozen
sections of myocardium taken from the same group of 12 patients.
Without exception, there was complete absence of these HIV
surface antigens indicating that the virus which had been
demonstrated within the myocardium using the polymerase chain
reaction was not replicating. Control sections of brain known to
contain replicating HIV did show positive staining, validating the
assay.
These results suggest that HIV is found commonly within the heart,
sometimes in high concentration. Any deleterious effects
attributable to the virus are unlikely to be caused by viral
replication. Concomitant factors such as the innocent bystander
response or synergy with another agent (for example, antioxidant
deficiency) may be relevant.
There are scattered anecdotal reports implicating selenium
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deficiency as a cause of cardiac dysfunction in HIV infection
(Zazzo et al 1988, Dworkin et al 1989). This is analogous to
Keshan disease, a naturally occurring cardiomyopathy found in
China which is potentially reversible with selenium supplementation
(Keshan Disease Research Group 1979). A subgroup of 30 patients
with various forms of HIV heart muscle disease participating in the
longitudinal echocardiographic survey underwent assay of selenium
serum. HIV control patients were selected on the basis of age, sex,
body mass index, risk group and stage of disease. It was found that
serum selenium concentrations lay well below the reference interval
in the majority of patients, and that those with heart muscle disease
had particularly low values, although statistical significance was not
achieved. These results suggest that deficiency of selenium either
alone or in combination with other trace elements is widespread in
the HIV population. Although a causal relationship has not been
established, heart muscle disease patients appear particularly likely
to suffer from selenium deficiency.
The issue of greatest clinical importance is the prognostic
significance of each of the various forms of heart muscle disease in
HIV infection. Over the course of a four year period looking at
296 patients, it was shown that the group with dilated
cardiomyopathy met a significantly earlier death from an AIDS
related condition than all the other heart muscle disease categories
and also those individuals with echocardiographically normal
hearts. This remained true even after correcting for the significantly
lower CD4 count found in this group and also when 13 dilated
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cardiomyopathy patients were paired with normal HIV controls
identical in all respects other than the presence of heart muscle
disease. However, death was rarely ascribed directly to cardiac
failure, corroborating the results of previous autopsy studies
(Cammarosano and Lewis 1985, Stewart et al 1989, Lewis 1989).
Borderline left ventricular dysfunction and isolated right ventricular
dilation did not appear to carry adverse prognostic implications,
possibly because of their underlying aetiology. Borderline left
ventricular dysfunction may be caused by myocarditis which is
potentially self-limiting and isolated right ventricular dilation
probably arises secondary to pulmonary disease which is often
reversible with the appropriate treatment, usually antibiotics.
The results of this study add considerably to our understanding of
the prevalence, aetiology and natural history of HIV heart muscle
disease. Many questions remain, however, and there are particular
areas which merit further study.
1. Cardiac myocytes may be damaged either directly by HIV or
indirectly through the activation of immunological
mechanisms. HIV has been shown to be present within the
heart, often in relatively high concentrations compared with
that within circulating lymphocytes, the principal target of
the virus. This militates against random contamination and
suggests specific targeting, possibly by cardiotropic variants
of the virus. Their existence could be confirmed by
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collecting HIV strains from a number of different tissues,
amplifying them with the polymerase chain reaction and
exposing them to length gel analysis.
2. The precise location of HIV within the myocardium also
remains unclear. The virus may be present within cardiac
myocytes themselves or within interstitial or endothelial cells
(Herskowitz et al 1993b). In situ hybridisation to date has
given conflicting results. More consistent information may
be obtained once the technique of in situ polymerase chain
reaction has been refined.
3. HIV induced death of cells within the myocardium may be
mediated either by a non-specific innocent bystander
response or through the expression of abnormal surface
antigens which are then attacked by native lymphocytes
which now recognise these cells as being "foreign". Novel
antigens may be detected on the basis of molecular weight by
homogenising and then purifying autopsy and
endomyocardial biopsy cardiac tissue using
ultracentrifugation and electrophoresis. The immunogenicity
of these antigens could be studied by blotting them onto
nitrocellulose and then punching this out into microtitre wells
containing lymphocytes from heart muscle disease and
control patients. Immunogenicity would be assessed by the
extent of lymphocyte proliferation. Not only would this
allow the immunogenicity of various antigens to be
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determined, but it might also be possible to establish whether
the lymphocytes from heart muscle disease patients are any
more susceptible to mitogenic stimulation compared with
their counterparts with normal cardiac function.
4. Any soluble products which are released such as
r-interferon, interleukin-6 and tumour necrosis factor could
also be assayed as these may be involved as immunological
mediators in the pathogenesis of HIV heart muscle disease.
The results of these studies might not only help to identify
HIV patients who are particularly susceptible to heart muscle
disease but also offer the prospect of specialised therapeutic
regimens such as the parenteral use of monoclonal antibodies
directed against mediators of the immune system including
the cytokines mentioned above (Wolff 1991).
5. Although the Edinburgh study appears to militate against a
direct relationship between opportunistic infection with
Toxoplasma gondii and cytomegalovirus in the development
of HIV heart muscle disease, serological assessment is prone
to inaccuracy. A more definitive answer may be obtained by
using in situ hybridisation, possibly in combination with the
polymerase chain reaction, to search within the myocardium
for genomic material specific to various opportunistic agents.
6. Low serum selenium concentrations appear to be widespread
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in HIV patients and is likely to be associated with other
deficiency states. The role of antioxidants in general merits
further assessment because not only may they play a part in
the development of end-organ damage, but also they are
potentially reversible at an early stage of disease using
dietary supplements. The time to development of heart
muscle disease may be retarded and even established cardiac
failure may be reversible to some extent. A comprehensive
nutritional survey followed by a study of the benefits of
supplementation therapy are long overdue.
7. This and other studies have provided anecdotal evidence that
palliative treatment with diuretics and vasodilators can
benefit some HIV patients with dilated cardiomyopathy. No
information is available about the potential long term
reduction in morbidity and mortality with vasodilator therapy
although this is now well established in non-HIV patients
with cardiac failure (The CONSENSUS Trial Study Group
1987, Pfeffer et al 1992, The SOLVD Investigators 1992).
Only a prospective trial drawing patients from several centres
can help to address this issue.
Major advances have been made in the treatment of opportunistic
infection and the progression of HIV disease itself. End-organ
damage and cardiac failure are likely to become increasingly
prevalent and will present substantial therapeutic and research
challenges. However, just as the scourge of syphilis in the early
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part of this century promoted research endeavours which added to
our understanding of the pathological basis of disease, so too does
HIV offer an opportunity for clinicians and academics working
closely together to establish the precise relationship between viral
infection and the development of heart muscle disease. In so
doing, not only may hitherto obscure pathological processes be
uncovered, but also hope offered to the millions of people around
the world who appear destined to succumb to intractable cardiac
failure in the early part of the next millenium.
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